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CHAPTER 1 
INTRODUCTION 
Since the chemotherapeutic treatment of haematological malignancies and 
solid tumors is becoming more aggressive and effective, an increasing 
number of patients will be at risk for granulocytopenia. Consequently, the 
improved outlook for these patients is jeopardized by the threat of 
infection. Next to neutropenia, many other factors may predispose these 
patients to infection with a wide variety of pathogens. Therefore, measures 
designed to prevent infections by reducing the risk of acquisition of 
potential pathogens and by preserving natural anatomic barriers, or early 
adequate therapy in case of infection, have been stressed in the 
literature. There is no doubt, that the last decade has witnessed an 
enormous improvement in the successful management of infectious 
complications in immunocompromised patients. Though changing medical 
practices contribute to the emergence of new pathogens and necessitate the 
development of new antimicrobial agents continuously. 
MAGNITUDE OF THE PROBLEM 
Although the advanced management of neoplastic diseases has increased the 
chance of "disease free survival", the majority of adult patients with 
acute leukemia are dying due to complications of chemotherapy during 
remission induction or maintenance therapy. Autopsy data from different 
centers show a remarkably stable incidence of infection as a major cause of 
death during the last 3 decades (see Table 1). Bleeding disorders, which 
have been the second major cause of mortality in these patients, is 
declining gradually; from 54% in the period 1954-1963 to 36% in the last 
decade. This may be attributed to the development of effective platelets 
transfusions (3). Between 1972 and 1985, in St. Radboud hospital 
(Nijmegen), 50« of the mortality in patients with acute leukemia was due to 
infectian and 43% due to bleeding disorders. 
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Table 1 Causes of death among patients with acute leukemia. 
Reference 
(1) 
(2) 
(3) 
Nijmegen** 
Period 
1954-1963 
1966-1972 
1976-1982 
1972-1985 
'Jurnber of 
patients 
354 
315 
109 
290 
Princi pal causes 
Haemorrhage* 
54% 
24% 
36% 
43% 
of 
Infect· 
72% 
74% 
68% 
50% 
death C D 
¡on*+ Other 
13% 
10% 
10% 
17% 
* Including haemorrhage accompanied by infection and other causes 
*+ Including infection accompanied by haemorrhage and other causes 
** Not published data 
FACTORS PREDISPOSING TO INFECTION 
Granulocytopenia is the single most prominent risk factor for infection. In 
addition to the actual granulocyte count (4), the duration and persistence 
of granulocytopenia (5), the functional integrity of the phagocytic system 
(6), antibody production, impairment of cell-mediated immunity (7) and 
disturbance of the physical defence barriers are important variables. Under 
normal circumstances a complex interrelationship of lymphocytes, 
neutrophils, macrophages, immunoglobulins, complement, and physical 
barriers provide protection against infecting organisms. Any qualitative or 
quantitative defect in one of these factors may predispose to infection. 
Defects may be disease related, as in haematological malignancies (8) and 
graft-versus-host disease after bone marrow transplantation (9,10), or 
secondary to treatment with irradiation and/or cytostatic drugs. The 
quantitative effects of these treatment modalities on the haematopoetic 
system are well recognized, but they also enhance the risk of infection by 
interference with the function of the remaining immunocompetent cells 
(11,12), and the integrity of the mucous membranes. Another port of entry 
may be the skin, as the vast majority of patients will have peripheral or 
central catheters (13) for administration of the cytostatic drugs and 
supportive therapy. A major source of infection is the endogenous gut 
flora of the patient. Colonization precedes infection (14) and admission 
alone increases the chance of acquiring potentially pathogenic strains 
(15,16). Van der Uaaij et al (17,18) have shown that preservation of the 
endogenous anaerobic microorganisms, that compose up to 99% of the gut 
flora, attribute to the resistance against colonization by transient, 
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potentially pathogenic germs. 
Finally it has to be mentioned that immunocompromised patients show 
an increased susceptibility for transmission of infectious agents by blood 
products/ contaminated intravenous fluids (19,20), foods, visitors and 
medical attendants (21). The spectrum of these infections is wide, 
including bacteria, viruses and fungi. It may be clear that not all 
granulocytopenic patients have the same risk of infection. Differences in 
the degree of impairment in neutrophilic and non-neutrophilie defences and 
differences in environmental circumstances may determine whether or not a 
granulocytopenic patient will become infected. 
SPECTRUM OF INFECTING PATHOGENS 
A minority of infections in the neutropenic patient are community acquired. 
In a retrospective analysis of all patients suffering from acute Leukemia 
treated in our clinic between 1975-1985, we found a microbiologically 
proven infection in 19% on first admission. The organisms found were 
similar to those causing infections in normal hosts, but there was a 
difference in terms of severity and duration. Gram-positive infections were 
mainly due to Staphylococcus aureus (2СШ and less frequently to 
Streptococcus pyogenus or to Strep, pneumoniae. Of all Gram-negative 
infections the predominant isolate was Escherichia coli (14%). Incidentally 
Klebsiella f Enterobacter, Proteus species or Pseudomonas aeruginosa were 
cultured. Twenty per cent of the community acquired infections were 
polymicrobial and H X proved to be oral candidosis. 
Hospital acquired infections occurred in 74% of the patients during 
induction and maintenance therapy, with an average of 1.5 infections per 
patient, (see Table 2 ). Septicemia and other infections due to 
Staphylococcus epidermidis , viridans streptococci and enterococci emerge in 
patients who have been hospitalized for some time. Staphylococcus 
epidermidis grown in blood cultures from patients with indwelling 
intravenous catheters should not be assumed to be a contaminant and may 
often be the cause of a genuine infection (22). This also holds true for 
Corynebacterium species, often refered to as "diphtheroids" (23). 
Superinfection with enterococci is a new and increasing problem. Although 
the mortality rate of these latter infections is rather low (24), the 
morbidity and costs of prolonged hospitalization and additional antibiotics 
should rtot be neglected. 
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The later occurring Gram-negative infections are mainly higly 
resistant enterobacteriaceae (see Table 2). The specific organisms most 
likely to be involved in nosocomial infections depends on the given 
infection pattern in a specific hospital or even a given ward or patient 
group (3). 
Non-bacterial infections are more likely to occur later during 
Table 2 iHcrobiologically proven infections in 270 patients with 
acute leukemia admitted from 1975-1985 St. Radboud hospital. 
Pathogens Total m Microorganisms 
Gram-positive 197 (41%) 
Gram-negative 131 (28%) 
Anaerobes A ( 1%) 
Polymicrobial 70 (15%) 
Mycosis 71 (15%) 
Staphylococcus epidermidis 
Staphylococcus aureus 
Streptococcus viridans 
Beta hemolytic streptococci 
Streptococcus faecalis 
Streptococcus pneumoniae 
miscellaneous 
Escherichia coli 
Klebsiella species 
Pseudomonas species 
Enterobacter species 
Proteus species 
miscellaneous 
30 
54 
21 
15 
10 
9 
δ 
43 
30 
26 
14 
5 
13 
(40%) 
(27%) 
(11%) 
( 8%) 
( 5%) 
( 5%) 
( 4%) 
(33%) 
(23%) 
(20%) 
(10%) 
( 4%) 
(10%) 
Candida species 
Aspergillus species 
Torulopsis species 
66 (93%) 
3 ( 4%) 
2 ( 3%) 
therapy. Fungal infections have to be considered when an antibiotic induced 
defervescense is followed by a new episode of fever, particularly in those 
patients in whom no bacterial cause could be identified. Invasive 
candidosis and aspergillosis are likely to occur in this setting and high 
mortality rates have to be expected (25-27). Transfusion associated 
hepatitis A and В may run a fulminant course (23). Patients, who have 
additional impaired cellular immunity are at great risk of reactivating or 
acquiring a herpes virus infection (29,30). Cytomegalovirus infections may 
induce life threatening illness in immunocompromised patients (10). 
Interstitial pneumonitis, manifesting itself as fever, dyspnoe and dry 
cough, .is one of the most feared complications after bone marrow 
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transplantation (9,31). The majority of cytomegalovirus infections is 
related to administration of blood products, especially leukocytes (32). 
Less frequent, but dangerous complications are infections by Toxoplasma 
gondii and Pneumocystes carinii , particularly if the inmunocompromised 
patient is being treated with corticosteroids (33). 
PREVENTION OF INFECTION 
Since the majority of infecting organisms in immunosuppressed patients 
arise from the endogenous microbial flora, eventually acquired during the 
patients hospitalization, it is not surprising that nursing in reverse 
isolation is only of limited value (ЗА). Maximal reduction in microbial 
contamination of the patient and his environment by the use of laminar air 
flou or filtered air, specially prepared food, and skin cleansing agents 
will prevent a small minority of the infections but may be accompanied by a 
considerable discomfort for the patients (35-37). Simple avoidance of 
contact with overt or well-known sources of infection seems to be 
sufficient in most cases (34). 
During the last decade oral nonabsorbable antibiotics have formed the 
backbone of the infection prevention regimens in order to reduce the 
endogenous microbial burden (38). Although there is a rational basis for 
this approach, studies performed until now have not shown that the use of 
oral nonabsorbable antibiotics alone has a definite and constantly positive 
effect in the prevention of infection. Next to the poor patient compliance 
with these antibiotics, suppresion rather than elimination of the 
endogenous flora is achieved, with the risk of rapid repopulation by 
virulent organisms and subsequent infection following accidently premature 
discontinuation. The importance of attempting to sterilize the 
gastrointestinal tract completely has been questioned by van der Waaij 
(39). He introduced as an alternative, partial decontamination or selective 
manipulation of the gut flora. He and his coworkers demonstrated that 
preservation of the host's anaerobic flora provides a resistance to 
colonization by exogenous aerobic potential pathogenic organisms. Several 
'antibiotics (co-trimoxazole, quinolones, polymyxins and low-dose 
aminoglycosides) are able to eradicate aerobic Gram-negative organisms and 
part of the staphylococci and miconazole, ketoconazole or amphotericin В 
are able to reduce fungi, while preserving the gastrointestinal anaerobes. 
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The concept of colonization resistance has been tested successfully in 
leukemia patients undergoing bone marrow ablative chemotherapy (18). The 
results are encouraging, but infections are not eliminated completely. For 
instance, food known to be highly contaminated by Gram-negative bacilli 
should be avoided at all time (40,41). Moreover, application of co-
trimoxazole alone has been associated with increased incidence of fungal 
infections (42), colonization and subsequent infection by resistant 
enterobacteriaceae (43-45) and prolongation of the granulocytopenia (46). 
Successful application of this approach requires combination therapy and 
close microbiological surveillance, so that the antibiotic regimen can be 
adjusted continously when new and/or drug-resistant organisms appear. This 
is both labor intensive and expensive. On the other hand, the clinical 
value of these surveillance cultures for identification of an organism 
responsible for a febrile period is low (47). Reviewing the infections 
occurring during the past decade at our haematological ward, we were able 
to predict the causative pathogen on the basis of surveillance cultures in 
8 out of 473 cases and in only one case this putative knowledge did have 
.implications for the empiric therapy. 
Several antimicrobial agents are under investigation as prophylaxis 
against specific infections which are common among the immunocompromised 
host. Co-trimoxazole was established to be capable of reducing the 
frequency of Pneumocystis carinii infections in highly susceptible patients 
(48). Acyclovir has been used successfully as prophylaxis against herpes 
virus infections in bone marrow transplant recipients (49). In our 
institute we have good experiences with cephaloridin suspension as a gargle 
to prevent colonization of the oropharynx by staphylococci. However 
application seems to be associated with an increased incidence of fungal 
infections. 
Profylactic administration of granulocyte transfusions to bridge the 
neutropenic period has been investigated. In most studies the results were 
disappointing (50). Moreover, a higher incidence of cytomegalovirus 
infections was registered in recipients of granulocyte transfusions (32). 
Both active and passive immunotherapeutic measures have been 
evaluated for protecting patients from infectious complications. Active 
immunotherapy may be hampered not only by the impaired antibody response 
due to the underlying haematological disease, but also by the concomitant 
immunosuppressive chemotherapy. Passive immunotherapy lacks this 
disadvantage and studies are being conducted with Pseudomonas antiserum, 
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anticytomegalovirus hyperimune globulins and antiserum to the core 
'glycolipid of Gram-negative bacteria or diphtheroids (51). The 
possibilities and limitations of manipulating the immuneresponse by 
transfer factor or interferon are still under investigation. 
DIAGNOSIS OF INFECTION 
IN GRANULOCYTOPENIC PATIENTS 
Despite profylactic measurements the majority of neutropenic patients will 
develop infections. The classic symptoms of inflammation (dolor, rubor, 
calor, tumor and functio laesa) are less clear in the patient with 
neutropenia. Especially fluctuation, exudation and ulceration are more 
closely related to the presence of granulocytes and may be reduced 
remarkably. But erythema may occur and pain and fever remains a reliable 
indication of a localized infection (52). Besides fever, positive physical 
examination or infiltrates on a chest x-ray may be indicative of pneumonia 
even in the absence of cough or sputum production. 
A continuing problem is the very high proportion of "infections" 
that never are documented microbiologically. Fevers of unknown origin may 
account for more than 50% of the febrile episodes (6). More aggressive 
investigation like bronchoscopy or open lung biopsy has only benefited a 
minority of patients (53-55). Moreover, fungal infection is hard to prove 
and the majority have been discovered after autopsy only (56). Serum 
conversion in case of viral infections may be absent due to the impaired 
immune system of these patients. 
The decision to initiate antimicrobial therapy must be based on 
substantially less hard data than in patients with a normal granulocyte 
count. Because it does not appear to be possible to determine reliably the 
granulocytopenic patient whose fever has an infectious origin, it seems 
best to assume that all patients who become febrile when the leucocyte 
count is less than 1000/mm are infected until proven otherwise. 
EMPIRIC TREATMENT 
OF THE FEBRILE GRANULOCYTOPENIC PATIENT 
Antimicrobial therapy in febrile neutropenic patients should be undertaken 
on an empirical basis, i.e. pending the results of the cultures. If 
adequate therapy is delayed, awaitiny microbiological confirmation, more 
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than half of the patients with an infection due to Gram-negative organisms 
will die during the first 48 hours (57). The primary objective of initial 
empiric therapy is to protect these patients from early death. Therefore/ 
the antibiotic regimen selected must be active against the major pathogens 
and in particular against Grara-negative bacilli. The incidence of 
infections due to Gram-positive organisms is increasing (22,58). In our 
institute the ratio Gram-positive/negative pathogens has increased from 
0.87 in 1975 to 3.2 in 1985. Despite the increased morbidity due to Gram-
positive bacilli, still half of the mortality in patients with acute 
leukemia dying from a bacterial infection, are caused by Gram-negative 
pathogens (See Table 3 ) . 
Table 3 Fatal Infections in Acute Leukemia (St. Radboud Hospital). 
Origin Bacterial infections Poly- Mycotic- No 
Period Gram + Gram - microbial infection isolate 
Pneumonia 
1972-1978 1 ( 3 % ) 8 (24%) - 5 (15%) 19 (58%) 
1979-1985 3 ( 7%) 5 (12%) - 16 (37%) 19 (44%) 
Septicemia 
1972-1978 4 (19%) 16 (76%) 1 (5%) 
1979-1985 14 (46%) 12 (40%) 2 (7%) 2 ( 7 % ) 
Infections caused by Gram-positive cocci are normally less aggressive and, 
consequently, offer more opportunity to adjust the antibiotic treatment 
scheme according to the sensitivity spectrum of the isolated 
microorganism(s). Despite their numbers, anaerobic bacteria rarely cause 
primary infection in granulocytopenic patients (Table 2 ) . Fungi, 
particularly candida species, can be a primary cause, but are more likely 
to be a problem in patients with protracted neutropenia who already have 
been treated with antibiotics (59,60). 
It is important to stress that the efficacy of an empiric antibiotic 
regimen must be evaluated for both initial treatment (the first 72 hours) 
and during the complete period of persisting granulocytopenia. Patients 
with extended granulocytopenia are at risk for secondary infectious 
complication and this risk is increasing with the duration of neutropenia, 
including resistant bacteria as well as nonbacterial pathogens. 
Initial empiric therapy traditionally consists of a two- or three 
drug '»regimen, usually comprising an aminoglycoside, a cephalosporin and/or 
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an antipseudomonal penicillin (61-91). Selection criteria are based on 
bactericidal spectrum, possible synergism, side effects and costs. No 
absolute superior combination has been described in a Large number of 
trials (See Table 4 ) . It seems appropriate to consider the susceptibility 
pattern in a given hospital or ward in determining the combination of 
choice. In the past it has been shown, that the success rate for Gram-
negative bacteremia will increase if the isolate is susceptible to both 
antibiotics in the treatment regimen, compared to those infections in which 
the susceptibility of the isolated pathogen is restricted to one of the 
drugs alone (57,92). Another important aspect of initial antimicrobial 
therapy is the emergence of Staphylococcus epidermidis associated with 
intravascular devices as an important pathogen with unpredictable 
susceptibility. Inclusion of broad spectrum anti-staphylococcal antibiotics 
in the initial regimen may be necessary in those cases. 
Table 4 Antibiotics and combination of antibiotics in the empiric 
treatment of febrile neutropenic patients 1972-1936. 
Drug regimen References Number Outcome 
episodes range (%) 
Three drug reginen 
Pen. + Ceph. + Aminogl. 72,77,83,84 
Pen. + Vane. + Aminogl. 78 
flonob. + Vane. + Aminogl. 81 
Two drug regimen 
Pen. + Aminogl. 
Ceph. + Aminogl. 
Pen. + Ceph. 
Honob. + Vane. 
Pen. + Vane. 
Ceph. + Vane. 
Monotherapy 
Ceftazidime 69,70,72,79,83,84 
Moxalactam 73 
Imipenem (+ ei lastin) 85 
Cefoperazone 87 
Gentamicin 91 
Pen = Broadspectrum-penici Hin, Ceph. = Cephalosporin, flonob. = llonobactam, 
Aminogl. = Aminoglycoside, Vane. = Vancomycin. 
435 
23* 
155* 
57-67% 
74% 
72% 
61,63-68,77,78,82,88,89,91 
63,68-71,73-75,82,86,87,91 
61-64,71,74,79-81,86,91 
81 
66 
84 
2543 
1072 
1392 
155* 
193* 
37* 
49-97% 
47-83% 
48-77% 
69% 
65% 
57% 
480 
29* 
79* 
22* 
122* 
43-80% 
73% 
67% 
71% 
22-53% 
* Single study. 
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Each antibiotic/ which is used in the treatment of febrile 
neutropenic patients has its own benefits and disadvantages. All major 
classes of antimicrobials: aminoglycosides, cephalosporins, and extended 
spectrum penicillins, meet the prerequisite of sufficient bactericidal 
activity (93). The use of aminoglycosides is associated with the risk of 
ototoxicity and nephrotoxicity, especially when repeated courses are 
necessary or if applied in combination with other potentially toxic drugs 
(94-96). The dose should be adjusted individually, ¡loreover, the efficacy 
of aminoglycosides depends on the severity of neutropenia. Without 
synergistic additional therapy no reliable activity in severely neutropenic 
patients can be expected (90,97). The older cephalosporins have a gap in 
activity against Gram-negative organisms, whereas the last generation shows 
suboptimal activity against Gram-positive cocci. They all lack useful 
activity against enterococcî (98). The anti-anaerobic activity of the 
antipseudomonal penicillins is a major disadvantage with respect to the 
colonization resistance. Other side effects of these drugs are the higher 
incidence of allergy, prolongation of neutropenia, hypokalemia, 
'interference with bloodclotting and high sodium content (65,71,99). 
The choice of an initial antimicrobial agent is not the only 
problem in the treatment of febrile neutropenic patients. Duration of a 
successful therapy and the attitude towards persistant fever are still 
controversial. It is an accepted policy now to narrow the spectrum of the 
antibiotic regimen in normal patients, as soon as the causative organism 
has been identified, avoiding unnecessary toxicity and risk of 
superinfection. However, in thç neutropenic patient continuation of the 
broadspectrum antibiotics seems to be preferable, since they provide 
systemic prophylaxis. The incidence of superinfections and relapses is 
reduced if the antibiotic treatment is continued (100). It is our policy to 
continue the antibiotic therapy in the successfully treated patients until 
2 days after subsidence of all symptoms in cases where the granulocytes are 
increasing, and for 4 days if no increase in the granulocyte count is 
registered. During treatment, the selective gut decontamination is 
continued if feasible. If not, it is resumed as soon as possible until 
granulocyte recovery. 
The issue is much more complex for the persistently granulocytopenic 
patient who remains febrile without demonstrable infection. One tends to 
switch antibiotics on the assumption that lasting fever represents an 
inadequate response or the emergence of resistant organisms. However, fever 
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may be worrisome, but in the absence of a deteriorating clinical condition, 
it does not necessarily reflect failure. The first step could be additional 
therapy against bacilli not covered by the initial empiric conbination. In 
case of progressive mucositis or perirectal tenderness addition of an anti-
anaerobic drug nay be considered. Antifungal therapy should be initiated 
empirically in neutropenic patients remaining febrile after broad-spectrum 
antibiotics in view of the risk of invasive fungal disease (101). If the 
adjustments of the antibiotic scheme do not induce defervescence, cessation 
of therapy seems warranted in order to avoid toxicity, risk of resistant 
superinfections and to save expenses, premising the patients condition is 
not poor or deteriorating. 
Another tenet of infection management is that foreign bodies like 
indwelling catheters, which are regularly used in these patients, should be 
removed when fever persists. In case of Gram-negative or fungal infections 
associated with intravenous devices this is most likely the only way to 
cure the patient. But in case of Gram-positive infections or fever of 
unknown origin an attempt to save the catheter may be well successful and 
justifiable (102,103). 
THE PLACE OF CEFTAZIDIME MONOTHERAPY 
IN FEBRILE NEUTROPENIC PATIENTS 
The benefits of employing a combination of antibiotics have to be balanced 
against the additional risk of toxicity. Whether combination therapy, 
aiming at synergy, remains necessary is currently of interest in the light 
of the availability of the third generation cephalosporins and cárbapenems. 
In studies of synergistic combination therapy in neutropenic patients 
Klastersky et al stated that a titre of 16 or more was associated with a 
better outcome (57,92). These new antibiotics achieve serum Levels over 100 
fold higher than the minimal inhibitory and bactericidal concentrations for 
Gram-negative bacteria. Their spectrum of activity includes Pseudomonas 
aeruginosa, Serratia, Citrobacter, Proteus species and to a lesser extend 
Enterobacter cloacae. The cephalosporins are less active against the 
staphylococci and streptococci and none achieve an effective serum level 
against enterococci. 
Ceftazidime, one of the "third generation" cephalosporins, is highly 
resistant to beta-lactamases (104) and has a broad spectrum of in vitro 
antibacterial activity (97,105). It is less effective against Gram-positive 
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organisms than imipenem, but has a higher activity against Pseudomonas 
species. Oral absorption is negligible and intravenous route is preferred. 
Peak ceftazidime serum concentrations of 70-72 mg/L are attained 
immediately after one gram (30 minutes) infusion. Mean peak levels between 
20-30 mg/L are achieved in a variety of tissues and body fluids. The volume 
of distribution is ussually between 15 and 20 L. The elimination half-life 
is 1.5-2.8 hrs. in healthy subjects. Apparently no metabolization occurs 
and the drug is eliminated largely by glomerular filtration. The half-life 
is prolonged in patients with moderate to severe renal impairment. 
Ceftazidime is generally well tolerated. The most commonly reported side 
effects are transient elevation of liver function tests (3.5-7Я), positive 
Coombs without signs of haemolysis (4.7%), skin rash (1.6-2.7%), and less 
frequently gastrointestinal reactions (2.4%). Discontinuation of therapy 
was necessary in 2.4% overall (106). 
Faced by the poor results of the combination gentamicin plus 
cefotaxin (in use in 1980 in our clinic) as empiric treatment of febrile 
neutropenic patients, and the favourable results achieved by ceftazidime 
alone in patients who failed on the initial combination, a prospective 
study was performed to compare these two regimens (69). Ceftazidime 
monotherapy proved to be significantly more effective than gentamicin plus 
cefotaxim. The inferior results of this combination was confirmed later by 
the studies of the European Organization for Research and Treatment of 
Cancer (82). The advantage of monotherapy, being easier to apply, the 
effectivity and low toxicity strengthed us to explore further the 
applicability of ceftazidime in febrile neutropenic patients. In the first 
study, we were forced to modify therapy in a small subgroup of patients 
with resistant Gram-positive infections. Consequently, in a second study we 
compared ceftazidime monotherapy with the combination of ceftazidime plus 
f lucloxaciHin in 100 febrile neutropenic patients in an attempt to 
increase the coverage against staphylococcal infections (79). Although 
there was a slightly better outcome for staphylococcal infections, the 
overall clinical and bacteriological cure rate was not improved by the 
combination. This was due partly to the occurrence of Gram-positive 
pathogens resistant to both ceftazidime and flucloxaciHin, and partly to 
the increase of superinfections in the group treated with the combination. 
Horeover, more than 10% of the patients treated with flucloxaciHin 
experienced a drug induced exanthematous rash. Comparing the cure rates of 
ceftazidime monotherapy to the results of combination therapy (Table 4 ) , it 
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was evident that this approach was successful as initial empiric therapy. 
However these data required further clinical confirmation as many questions 
remained unanswered. 
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CHAPTER 2 
OUTLINE OF INVESTIGATION 
The aim of this thesis was to explore further the strong and weak aspects 
of ceftazidine nonotherapy in the empiric treatnent of febrile neutropenic 
patients. 
Chapter 3: Gran-positive microorganisms are less susceptible for 
ceftazidime in vitro, than the earlier generation cephalosporins. It was 
noticed, that patients who failed on initial ceftazidime monotherapy due to 
infections by Gram-positive pathogens did well after additional therapy 
with cephalothin. Based on the favourable results achieved in these 
patients, we performed a prospective randomized study of ceftazidime plus 
cephalothin versus ceftazidine alone as empiric therapy in febrile 
neutropenic patients. The theoretically preferable combination of 
ceftazidine plus vancomycin could not be explored, because both were 
investigational drugs at that time in The Uetherlands. 
Chapter 4 The conventional formulation of ceftazidime is blended with 
sodium carbonate in order to improve the solubility. On di&olving this 
blend, the pressure in the vial may increase, expelling part of its 
contents and spreading a fishy odor, ¡loreover, the generated carbondioxide 
may form numerous small bubbles in the infusion lines. A new formulation, 
ceftazidime arginine which should lack these sequella was developed. In 
this chapter the results of comparing the effectivity and safety of both 
formulations in the empiric treatnent of febrile neutropenic patients, are 
reported. 
Chapter 5 Neither flucloxaciHin, nor cephalothin did add substantially to 
the efficacy of ceftazidime when given in combination as empiric therapy 
for febrile neutropenic patients. Modification of therapy remained 
necessary in a minority of the patients. Vancomycin proved to be a reliable 
drug in case a failure due to Gram-positive infection did occur during 
previous studies. Therefore, teicoplanin, a new glycopeptide antibiotic, 
with theoretically less toxicity and practical advantages was assessed as 
rescue therapy for ceftazidine monotherapy in an open study; the results 
are described in this chapter. 
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Chapter 6 Early infectious death in the immunocompromised host is mainly 
associated with Gram-negative infections. Any empiric therapy in 
neutropenic patients must provide evidence of efficacy in Gram-negative 
infections; the bottle-neck has been mainly failures due to infections 
caused by Pseudononas aeruginosa. In this chapter a retrospective study is 
reported, analyzing the effectivity of ceftazidime alone in case of 
bacteriologically documented Pseudomonas aeruginosa infections. 
Chapter 7 Conventional conbination therapy is associated with well known 
side effects. Among others, possible nephrotoxicity is a natter of concern 
in case of fever in bone marrow transplant patients, due to the interaction 
of cyclosporin-Α and notably aminoglycosides. The consequences of the 
adninistration of ceftazidime for the kidney function of patients treated 
with cyclosporin-Α after allogeneic bone marrow transplantation are 
reported in this study. 
Chapter 8 The most frequently reported side effect of drugs is an allergic 
skin reaction. A higher incidence of drug associated toxicodermia has been 
found in some diseases. '.Je explored the incidence of skin reactions due to 
cephalosporins and other drugs in patients suffering from acute non 
lymphocytic leukemia. 
Chapter 9 Fever is the most reliable indication of infection in the 
neutropenic patient. Still subtle symptons of localized infections may be 
discovered on examination. Conventional combination therapy proved to be 
less effective when tissue invasion occurs. We reassessed alt patients 
treated with ceftazidime alone during four studies in order to define the 
possible role of cefiazidime monotherapy in febrile neutopenic patients 
with a localized infection. 
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S U M M A R Y 
In a prospective, randomized study, ceftazidime monotherapy was compared 
with a combination of ceftazidime plus cephaLothin in 102 febrile 
neutropenic patients. Thirty bacterioLogically documented infections, of 
which 23 were bacteremias, in 4¿l clinically assessable patients were 
treated with ceftazidime alone. Twenty-four bacteriologically proven 
infections, of which 18 were bacteremias, in 42 clinically assessable 
patients were treated with a combination of ceftazidime and cephalothin. 
The clinical response rates in assessable patients were 77% for ceftazidime 
monotherapy and 88% for the combination. The bacteriological clearance rate 
was 70% for ceftazidime monotherapy and 79% for the combination. Efficacy 
against Gram-negative pathogens appeared to be excellent, with 93% 
clearance for ceftazidime monotherapy and 100% clearance for the 
combination. The bacteriological clearance of Gram-positive infections was 
only 60% for both arms, with failures mainly due to Streptococcus faecalis 
and Streptococcus sanguis, primarily resistant to both ceftazidime and 
cephalothin. After addition of vancomycin to those infections which did not 
respond to empiric therapy, bacteriological clearance rates of 94% 
(ceftazidime plus vancomycin) and 90% (ceftazidime and cephalothin plus 
vancomycin) were achieved. Three superinfections were registered in the 
ceftazidime group and two in the combination group. Other adverse events on 
ceftazidime were minimal and not enhanced by combination with cephalothin. 
It is concluded that ceftazidime is an effective drug for the empiric 
treatment of febrile neutropenic patients, especially if one is prepared to 
modify therapy if resistant Gran-positive strains or mycotic infections are 
encountered. Neither the clinical nor bacteriological cure rates could be 
substantially improved by adding cephalothin to ceftazidime in initial 
empiric treatment of febrile neutropenic patients. 
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INTRODUCTION 
Despite substantial improvenent in supportive care, infection remains the 
major cause of Morbidity and mortality in patients with bone narrow failure 
secondary to malignant diseases or cytotoxic treatment. Early institution 
of enpiric antibiotic therapy has become standard practice for the initial 
management of febrile episodes in neutropenic patients. Synergistic 
schedules conprising two or three drugs, including aminoglycosides have 
been used and early death due to inadequately treated bacterial infections 
has been largely overcome. However concern for nephrotoxicity and 
ototoxicity can limit the use of aminoglycoside containing schedules, 
especially in the growing group of patients treated concomitantly with 
other potentially nephrotoxic drugs such as amphotericin-D, cisplatinum, 
and cyclosporin-Л. Ceftazidime, in view of its excellent Gram-negative 
spectrum in vitro (10,14), was shown to be comparable to the established 
aminoglycoside containing schedules in different studies as reviewed by 
Pizzo (11) and offers the opportunity of monotherapy in the febrile 
neutropenic patient. 
We have previously assessed the role of ceftazidime as empiric 
monotherapy for febrile episodes in granulocytopenic patients in two 
randomized comparative trials. In the first study (3) ceftazidime was shown 
to be significantly superior to a conbination of gentamicin and cefotaxime. 
Decause of the lesser activity of ceftazidime against Gram-positive 
infections, we were forced to modify the initial ceftazidime monotherapy in 
a small subgroup of patients. In the second comparative trial (4) 
flucloxaciI lin in combination with ceftazidime did not improve the efficacy 
of ceftazidime monotherapy. This was partly due to Gram-positive organisms 
found to be initially resistant to both drugs, partly caused by emerging 
resistance to f lucloxaci H i n , and to more superinfections in the group 
treated with the conbination schedule. Patients who failed to respond to 
ceftazidime alone or to the combination with flucloxaciHin were switched 
successfully to the combination of ceftazidime plus cephalothin. Hence, it 
was decided to compare a combination of ceftazidime plus cephalothin with 
ceftazidime alone prospectively. Furthermore it was not possible to 
evaluate the combination of vancomycin plus ceftazidime as both were 
investigational drugs in The Netherlands at that time. The actual study 
protocol was agreed by the local Ethical Committee. 
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PATIENTS AND METHODS 
This study was performed at the division of Hematology and Oncology, 
University Hospital St. Radboud, Nijmegen, The Netherlands, from March 19S4 
to Ilarch 1985. All consecutive patients over 14 years of age with an 
absolute granulocyte count of less than 1,000/mm , who became clinically 
septicemic with a tenperature of 33.5 С or more in the absence of an 
obvious non-infectious cause of fever were eligible for the study. 
Exclusion criteria were: a history of allergy to cephalosporins or systemic 
treatment with antibacterial agents in the previous 72 hours, except for 
oral co-trimoxazole as part of selective gut decontamination. All patients 
were nursed in reverse isolation and received prophylactically selective 
gut decontamination with co-trimoxazole, polymyxin-B and ketoconazole as 
previously described (4). 
Pretreatment evaluation included a complete history, physical 
exanination and cultures from the blood, urine, mouth, nose, throat, 
sputum, and any clinically suspicious lesion. Antimicrobial disc 
susceptibility testing was done according to the method of Kirby Bauer (2). 
Discs containing 30 ncg ceftazidime were used. Laboratory investigation 
included hemoglobin and hematocrit, thrombocyte count, leukocyte count and 
differential, serum creatinine, glutamic-oxaloacetic transaminase, glutamic-
pyruvic transaminase and urinalysis which were performed as previously 
described (4). 
After informed consent was obtained, the patients were randomly 
allocated to receive either ceftazidime alone (2 g intravenously every S 
hours) or a combination of ceftazidime (2 g intravenously every 8 hours) 
plus cephalothin (2 g intravenously every 6 hours), all as 30 minute 
infusions. When systemic therapy was started, selective gut decontamination 
was terminated except for the antifungal compound. The empiric therapy was 
evaluated at 72 hours and modified or substituted only if the patient had 
not responded, unless adverse reactions or isolation of a pathogen 
resistant to the antibiotic(s) administered in the presence of a 
deteriorating clinical status urged an earlier change in therapy. In 
general therapy was continued until the patient was free of symptoms of 
infection for 4 days or for 2 days in cases in which the granulocyte count 
had increased to at least 1000/mm. 
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Clinical responses were classified as: (a) Success, if all clinical 
signs and synptoms subsided on the enpiric regimen without evidence of 
infection or recrudescence of fever at the tine the antibiotics were 
discontinued, nor during follow up; (b) Success with modification, if 
resolution of infection occurred only after addition of other agents to the 
empiric treatment reginen; (c) Failure, if there was no clinical response 
to initial therapy, even after treatment modification, and alternative 
therapy had to be given, or death occurred within 72 hours: (d) All those 
cases which proved to be viral or fungal infections, or when the protocol 
was violated, were classified as unassessable. 
Microbiological responses were defined as: (a) Success, if the 
original causative organism was eradicated; (b) Success with modification, 
if the original causative organism could be eradicated only after 
nodification ; (c) Failure if cultures remained positive; (d) Cases were 
bacteriologically unassessable for the same reasons as mentioned in the 
clinical definition supplemented by those for whom no organism could be 
isolated. Any infection occuring during treatment and not recognized as the 
initial causative organism was defined as a superinfection if further 
treatment was required. All new isolates without apparent signs of 
infection and not requiring treatment were defined as colonizations. 
RESULTS 
One-hundred and two patients were included in the study. Septicemia and 
bronchopneumonia proved to be the main infections. Underlying disease, 
degree of granulocytopenia, mean age, and weight were evenly matched in 
both study groups. The proportion of women was higher,in the ceftazidime 
monotherapy group compared to the group with combination therapy, but the 
difference was not significant (Table 1 ) . Fifty-one patients were allocated 
to both study arms. (See flow chart) Three patients in the ceftazidime 
group (2 fungal infections, 1 drug fever), and nine patients treated with 
cefazidime plus cephalothin (2 proven viral infections, 6 fungal 
infections, 1 drug fever), were unassessable for response. Details of the 
unassessable patients are summarized in Table 2. 
The results of treatment are shown in Table 3 and 4. Initial empiric 
therapy was successful in keeping alive 96% of patients treated with 
33 
Flow chart all entered patients 
102 Patients randomized 
Ceftazidime 
51 
Ceftazidime + 
cephalothin 
51 
Unassessable 
Clinical 
assessable 
Bacterlologically 
undocumpnl cd 
v. 
Ч
2 
N 0 
Drug fever 
Fungal infections 
Viral infections 
J 
Success initial drug(s) 
7 Success with modification 
Failure 
Sft 
1*2 
\. I 
w 417 Success initial drug(s) 
M Failure 
// 
'/ 
Doctcriologically 
documented JO 
1 Success initial drug(s) 
7 Success with modification 
2 Failure 
„ ^ 
24 
ceftazidine 
monotherapy, when 
evaluated after 72 
hours of therapy. 
One patient with a 
positive blood 
culture of 
Escherichia coli »as 
admitted in septic 
shock and died after 
only one dose of 
ceftazidime and one 
patient treated with 
ceftazidine 
monotherapy died on 
the third day due to 
Candida pneumonitis, 
confirned at 
autopsy. For 
ceftazidine plus 
cephalothin the initial empiric therapy, evaluated at 72 hours, was 
successful in the prevention of early fatal outcome in 98% of the patients. 
One patient with gastric carcinoma and paralytic ileus developed a Candida 
albicans plus Escherichia coli septicemia and died on the third day of 
treatment due to persisting shock. 
Although the data are not shown in the tables, ceftazidime as empiric 
nonotherapy was successful in 72% of all cases (including assessable and 
unassessable patients) with a return of temperature and clinical conditions 
to normal; a further 14% responded to additional antibiotics, and 2% to 
antifungal agents. Thirty-seven out of 51 (72%) febrile episodes treated 
with Leftazidime plus cephalothin responded clinically, a further 6% 
responded after the addition of other antibac^erials, and 6% after addition 
of antifungals. 
Analysis of the assessable cases only showed that thirty-seven (77%) out of 
43 patients were successfully treated with ceftazidime alone, and a further 
15% responded to additional antibiotics. Ceftazidime plus cephalothin as 
empiric therapy was successful in 37 (38%) of 42 clinically assessable 
patients; and a further 7% responded to additional antibiotics. 
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TABLE I 
Clinical data on treated patients 
Treatment 
Ceftazidime 
No. of patients (men/women) 
Mean age (range) years 
Underlying disease (No of patients) 
Acute leukemia 
Myeloproliferative syndrome 
Malignant lymphoma 
Aplastic anemia 
Solid tumors 
(Of which patients with bone marrow transplantation) 
No of patients with bacteriologically proven infections 
Infection sites (No of patients) 
Fever of unknown origin 
Septicemia 
Upper respiratory tract 
Lower respiratory tract 
Skin and soft tissue 
No of patients with two unique Infection sites 
No (X) of patients with granulocyte count 
at the start of treatment: < 250/mm 
250- SOO/mra1 
Ю\-І000/т? 
51 (24/27) 
42 (14-78) 
27 
6 
6 
5 
7 
(11) 
31 
16 
23 
7 
9 
5 
27 (53%) 
17 (33%) 
7 О«) 
Ceftazidime and 
Cephalothin 
51 
40 
(30/21) 
(15-74) 
27 
7 
5 
4 
β 
( 5) 
23 
18 
4 
10 
5 
25 (49%) 
16 (31%) 
10 (20%) 
TABLE 2 
Non bacterial origin of fever and unassessable patients. 
Origin of fever 
Ceftazidime monotherapy 
1. Bronchopneumonia: Torulopqis g labrata Resistant 
2. Bronchopneumonia: Candida albicans + Resistant 
Ps. aeruginosa Susceptible 
Susceptibility Rescue scheme Outcome 
Amphotericin-B Success. 
Died on third day Autopsy 
confirmed C. albicans/ Ps. 
aeruginosa was eradicated. 
3. Drug fever to earlier instituted cephalothin gargle. Subsided after withdrawl of the drug. 
Ceftazidime plus Cephalothin 
1. Bronchopneumonia Parainfluenza virus Resistant 
2. Bronchopneumonia: Parainfluenza virus Resistant 
3. Bronchopneumonia: Candida albicans + Resistant 
Escherichia coli Susceptible 
4. Bronchopneumonia: Candida albicans + Resistant 
Bacleroides melanogemcus Resistant 
5. Pharyngitis: Candida albicans Resistant 
+ Septicemia: Proteus mirabilis + Susceptible 
Staphylococcus "ëpidermidis Susceptible 
None 
None 
Miconazole 
None 
Miconazole 
Erythromycin 
Miconazole 
None 
None 
Success 
Success 
Success 
Eradicated 
Died fifth day of onset 
without eradication. 
Success 
Eradicated 
Eradicated 
6. Septicemia: Candida albicans 
7. Septicemia: Candida tropicalis 
θ. Septicemia: Candida albicans + 
Escherichia coli 
Resistant 
Resistant 
Resistant 
Susceptible 
Amphotericin-B Success 
Miconazole Success 
Hone Died third day, persistant 
shock, no eradication, 
9. Drug fever by anti thymocyte globulin treatment. Subsided after finishing ATG. course. 
TABLE 3 
Results of therapy in assessable patients 
Parameter 
Ceftazidime Ceftazidime and 
Cephalothin 
No of assessable patients 
Days of therapy with ceftazidime 
(Itean ± Standard deviation: (range)) 
Clinical outcome No (Z) of patients: 
Cure empiric therapy 
Cure modified therapy 
Failure 
Bacteriological outcome in documented infections 
No (%) of patients: 
Eradication 
Eradication after modification 
Failure 
Bacteriological outcome in septicemia 
No (%) of patients: 
Eradication 
Eradication after modification 
Failure 
Clinical outcome in bacteriologically qndocumented 
infecions No (%) of patients: 
Eradication 
Failure 
G r a n u l o c y t e count (%) of p a t i e n t s a t t i n e of r e s p o n s e * 
< 250/mra, 
250- 500/mm1 
•ЮІ-ІООО/іш3 
48 42 
9.0 ± 5.0 (0.3-31) .7 ¿ 3.6 (1.5-23) 
37 (77%) 
7 (15%) 
4 ( 8%) 
30 
21 (70%) 
7 (23%) 
2 ( 7%) 
23 
15 (65%) 
6 (26%) 
2 ( 9%) 
18 
17 (94%) 
1 ( 6%) 
20 (54%) 
13 (35%) 
4 (11%) 
37 
3 
2 
(88%) 
( 7%) 
( 5%) 
24 
19 (79%) 
3 (13%) 
2 ( 8%) 
15 
2 
1 
18 
15 
17 
5 
18 
(83%) 
(11%) 
( 6%) 
18 
(100%) 
(40%) 
(4Ь%) 
(14%) 
+ For successfully treated patients. 
In the ceftazidime group 30 out of 48 assessable patients had 
bacteriologically documented infections; 21 (70%) out of 30 responded to 
monotherapy. One patient died due to myocardial infarction on the fourth 
day without signs of infection, or positive cultures at autopsy'. Although 
it was a bacteriological success, this patient was regarded as a clinical 
failure. Seven patients responded to modification with vancomycin, all with 
infections due to Gram-positive organisms. And two were failures despite 
modification. Of 42 assessable patients treated with ceftazidime plus 
cephalothin, 24 had bacteriologically documented infections. Nineteen (79%) 
responded to the initial therapy and 3 after modification. 
The bacteriological results, based on positive cultures obtained 
before treatment, are shown in Table 5. There were no differences between 
both study groups. Twelve out of 20 Gram-positive organisms were eradicated 
by ceftazidime alone and 8 out of 14 were eliminated by ceftazidime plus 
cephalothin. All but one Gram-negative organisms were eradicated by 
ceftazidime monotherapy and all by the combination therapy. A 
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TABLE A 
Clinical successes after modification and' failures of therapy 
Original isolate (Superinfection) Ceftazidime susceptibility Rescue scheme and outcome 
(original/ superinfection) 
Ceftazidime monotherapy 
Success after modification 
1. Strep, sanguis (blood) 
2, H. influenzae (sputum) 
Susceptible (persisting) Vancomycin - eradicated 
(S. aureus (blood)) 
3. S. aureus (soft tissue) + 
Strep, faecalis (soft tissue) 
Susceptible (eradicated) 
/intermediate 
Resistant 
resistant 
vancomycin - eradicated 
(S. epidermidis (blood)) /resistant 
4. S. epidermidis (blood) Resistant 
5. H. influenzae (sputum) + 
S-haemolytic Strep, (blood) 
6. S. epidermidis 
7. Strep, faecalis 
Failure 
Vancomycin 
vancomycin 
vancomycin 
eradicated 
eradicated 
eradicated 
Vancomycin - eradicated 
Susceptible (eradicated) 
Susceptible (persisting) 
Resistant 
Resistant 
Vancomycin 
Vancomycin 
Vancomycin 
eradicated 
eradicated 
eradicated 
1. E« coli (blood) 
2. Strep, sanguis (blood) 
Recurrence Strep, sanguis 
3. E. coli (sputum) + 
!t. pneumoniae (sputum) 
Susceptible 
Susceptible 
Resistant 
Susceptible (eradicated) 
Susceptible (eradicated) 
Died after first dose 
Vancomycin (died) 
Died on fourth day after 
myocardial infarction. 
4. No pathogen isolated* Patient died (after initial improvement) due to massive gastro intestinal bleeding. 
Ceftazidime plus cephalothln 
Success after modification 
1. Strep, sanguis (blood) 
2. Strep, sanguis (blood) 
(C. albicans (sputum)) 
3. E. coli (peri-anal fistula) + 
Strep, faecalis (peri-anal fistula) + 
S. epidermidis (peri-anal fistula) 
Failure 
Intermediate (persisting) 
Susceptible (persisting) 
/resistant 
Susceptible (eradicated) 
resistant 
resistant 
Vancomycin 4- ampiclllin 
eradicated 
Erythromycin + amikacin + 
vancomycin eradicated 
amphoteric m-B eradicated 
Ampicillin 
ampiclllin 
eradicated 
eradicated 
1. S. aureus (blood) + 
B-baemolytic Streptococcus (blood) 
2. Strep, faecalis (sputum) 
Susceptible 
Susceptible 
Intermediate 
After initial improvement 
died due to ARDS. 
Vancomycin. Died due to 
pulmonary haemorrhage. 
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bacteriological clearance was achieved in 25 out of 34 (74%) assessable 
initial isolates by ceftazidime alone. In 24 out of 30 (80%) cases the 
causative organisms were eradicated by ceftazidime plus cephalothin. 
TABLE 5 
Distribution of pathogens and results of therapy by pathogen 
Organism* 
S. aureus 
S. epidermidis 
Streptococcus group A 
Streptococcus sanguis 
Streptococcus faecalis 
Streptococcus vindans 
H. influenzae 
E. coli 
Klebsiella pneunoniae 
Acinetobacter species 
Pseudomonas aeruginosa 
Ceftazid 
S 
4 
4 
3 
1 
5 
1 
2 
5 
M 
1 
2 
1 
1 
2 
ime 
F 
1 
1 
Ce 
S 
1 
4 
2 
1 
2 
5 
5 
1 
3 
ftazidime and 
Cephalothin 
M F 
1 
1 
2 
1 1 
S = success, M = success after modification, F = failure 
* Unassessable cases are not included (summarized m Table 2). 
Seventeen out of the 18 (94%) assessable/ bacteriologically 
undocumented infections were cured with ceftazidime alone; one died due to 
massive gastrointestinal bleeding after initial improvement. All 18 (100%) 
assessable patients with bacteriologically undocumented infections 
responded to the combination therapy without modification. 
At the tine of response the majority of the successfully treated 
patients were still profoundly neutropenic (Table 3). Twenty (54/Í) patients 
had less than 250 granulocytes per m , compared with 15 (402) in the 
ceftazidime plus cephalothin group. None of the successfully treated 
patients showed an increase of the neutrophil count above lOOO/mm . 
During ceftazidime monotherapy/ three superinfections were 
registered: one Staphylococcus epidermidis , one Staphylococcus aureus and 
one Candida albicans, all organisms resistant to ceftazidime. In two 
patients, who received ceftazidime plus cephalothin, superinfections with 
organisms resistant to both drugs occurred: one Clostridium difficile and 
one Candida albicans. 
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One patient, treated with ceftazidime alone, suffered from drug 
fever and a skin rash; while two more patients developed exanthema. One 
patient, treated with ceftazidime and cephalothin, showed a transient rise 
of glutamic-oxaloacetic and glutamic-pyruvic transaminases. Hone of the 
patients had any sign of nephrotoxicity as measured by serum creatinine 
levels or of ototoxicity, fio local reactions to the drugs were seen. 
DISCUSSION 
The data from this study and others (3-6,12), show that ceftazidime alone 
or in combination with another antibacterial gives excellent coverage 
against Gram-negative infections in the immunocompromised host, a 
prerequisite for any empiric treatment in this patient group (11). Increase 
of granulocyte count, which is associated with a better outcome (1) was not 
an important factor in these results. If judged after 72 hours treatment, 
ceftazidime proved to be a safe drug for empiric treatment in the 
neutropenic patient, with a survival rate of 96%. Primarily resistant Gram-
positive infections , mainly due to Strep, sanguis and Strep, faecal is, 
necessitated modification of therapy in both arms of the study without 
unacceptable mortality. A moderately better outcome for Staph, aureus and 
Staph, epidermidis was found in the combination arm without reaching 
statistical significance; Five out of 6 (33%) staphylococcal infections 
were cured by the combination, versus 8 out of eleven (73%) by ceftazidime 
alone (py0.1 Chi square with Yates correction). No antagonism was seen with 
ceftazidime and cephalothin. 
The outcome of modification with vancomycin was satisfactory in both arms. 
Inclusion of this more toxic drug in initial empiric treatment may have 
improved the results (13), but this policy would have been beneficial for 
less than 10% of the patients in this study. Furthermore no patients 
succumbed as a result of omission of vancomycin. So by modification, if 
required, after 72 hours we avoided unecessary administration of vancomycin 
to the majority of the patients. 
Concern has been expressed about double beta-lactam therapy in the 
immunocompromised host, especially for inducing beta-lactamase and 
resistance of Gram-negative micro-organisms (15), or inducing resistance 
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against a beta-lactamase susceptible compound (7). Ceftazidime has proven 
to be a weak beta-lactamase inducer (9). Besides the numbers of infecting 
strains are usually low in neutropenic patients so it is less likely that 
stable derepressed mutants will be encountered. In this study there was no 
evidence of reduced susceptibility in the double beta-lactam combination 
against Gran-negative organisms. Neither in the previous study, in which 
cephalothin served as a rescue scheme for the treatment of infections 
caused by Gram-positive organisms resistant to ceftazidime (4), nor in this 
study was induction of resistance observed. The only failures were due to 
primarily resistant strains. 
Toxicity of ceftazidime was ninimal, according to the data from the 
literature (3); no aggravation of toxicity was seen in combination with 
cephalothin in this study. 
In conclusion, combination of ceftazidime with an anti-
staphylococcal penicillin (4), aminoglycoside (6), or cephalothin did not 
improve the results of ceftazidime alone. Ceftazidime seems to be a safe 
and effective drug for monotherapy in the immunocompromised host, offering 
the opportunity to avoid the aminoglycosides and their inherent 
nephrotoxicity and ototoxicity. However, using monotherapy one should be 
prepared to modify therapy in case resistant Gram-positive strains or 
mycotic infections are encountered. 
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CHAPTER 4 
CEFTAZIDIME MONOTHERAPY AS EMPIRICAL TREATMENT IN 
FEBRILE NEUTROPENIC PATIENTS : A PROSPECTIVE 
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SUMMARY 
Ue conpared in a prospective randomized trial the efficacy and safety of 
ceftazidine sodium carbonate salt (CAZ-NA) to an arginine formulation of 
ceftazidime (CAZ-ARG) as empirical Monotherapy in 100 febrile neutropenic 
patients. Dissolving CAZ-NA often causes an unpleasant fishy odour and 
bubbles in the infusion lines, due to the generation of carbon dioxide; CAZ-
ΛΠΰ lacks these undesirable features. The clinical cure rate for CAZ-ÍJA was 
91« and for CAZ-AHG 03%. Fourty-two infections could be confirmed 
bacteriologically. Bacteriological cure rates were &7'/. for CAZ-NA and 81% 
for CAZ-ARG respectiuely. Only one infection-related fatal outcome (CAZ-
ARC; Corynebactenum parvum) occurred during the first 3 days of therapy. 
All failures of treatnent in bacteriologically proven infections were in 
patients with Gram-positive infections. The nursing staff found CAZ-Arg 
considerably easier to handle than CAZ-.ІА. Adverse events were negligible 
in both arms. Ceftazidime was confirmed to be safe and effective as 
empirical monotherapy in febrile neutropenic patients. CAZ-ARG is as 
effective and as safe as CAZ-IIA without the above mentioned side-effects. 
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INTRODUCTION 
Therapeutic approaches to haematological and malignant diseases are 
becoming more aggresive and effective, and consequently an increasing 
number of patients will be at risk for infections. Early institution of 
empiric antibiotic therapy has become standard practice for the initial 
management of febrile episodes in neutropenic patients, ilultiple empirical 
antibiotic regimens have been evaluated over the years and have 
demonstrated an overall efficacy rate of 65-75%. The main differences 
between these various regimens are the occurrence of side effects such as 
nephrotoxicity, ototoxicity, bleeding disorders and suppressive effect on 
the recovery of neutropenia (Dodey, et al, 1976; Fainstein, et al, 1934; 
Keating, et al, 1979; Uinston, et al, 19G2). Uith the development of beta-
lactan antibiotics with an extended spectrum especially against Gram-
negative organisms (Morris, Guenthner, G Wenzel, 1985; Rolinson, 19G6) 
nionotherapy became a possible new option in the empirical approach to the 
febrile neutropenic patient (Donnelly, et al, 1985; Fainstein, et al, 19£5; 
Pizzo, et al, 1985; Pizzo, et al, 1986; Ramphal, et al, 19o4). Uè have 
previously assessed the role of ceftazidime (CAZ) in this group of patients 
and found it to compare favourably uith the established combination 
schedules (De Pauw, et al, 1983; De Pauw, et al, 1935a; De Pauw, et al, 
1985b), offering the possibility to avoid antibiotic related toxicity 
(fleyers, 1985; Verhagen, et al, 1986). 
The marketed formulation of ceftazidime sodium carbonate (CAZ-NA) 
however has a practical drawback: dissolving the powder causes a fishy 
odour and non-toxic bubbles of carbon dioxide in the infusion lines. 
Therefore a new formulation, ceftazidime arginine (CAZ-ARG), which lacks 
these properties was developed. We compared the efficacy and safety of both 
compounds in a prospective randomized study in the empiric treatment of 100 
febrile neutropenic patients. 
PATIENTS AND METHODS 
This study was performed at the Division of llaematology. University 
Hospital St. Radboud, ïlijmegen. The .'letherlands, from March 1985 to Januari 
1936. All consecutive patients over 14 years of age with an absolute 
granulocyte count of less than 1000/шп , who became clinically septicaemic, 
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with a temperature of 38.5 С or more in the absence of an obvious non­
infectious cause of fever, were eligible for the study. Exclusion criteria 
were: a history of allergy to cephalosporins or systemic treatment with 
antibacterial agents in the previous 72 hours, except for oral co-
trimoxazole as part of selective gut decontamination. 
All patients were nursed in reverse isolation and received prophylactically 
selective gut decontamination with co-trinoxazole, polymyxin-B and 
ketoconazole as previously described (De Pauw, et al, 1935). Pretreatment 
evaluation included a complete history, physical examination and cultures 
taken from the blood, urine, mouth, nose, throat, sputum, and any 
clinically suspicious lesion. Antimicrobial disc susceptibility testing was 
done according to the method of Kirby Bauer (Dauer, Kirby, ß Sherris, 
1966). Discs containing 30 meg CAZ were used. Laboratory investigation 
included haenoglobin and haenatocrit, thrombocyte count, leukocyte count 
and differential, serum creatinine, glutamic-oxaloacetic transaminase, 
glutamic-pyruvic transaminase and urinalysis which were performed as 
previously described (De Pauw, et al, 1985). 
After informed consent was obtained, the patients were randomly allocated 
to receive either CAZ-NA or CAZ-AHG (both 2 g intravenously every 3 hours). 
When systenic therapy was started, selective gut decontamination was 
terminated except for the antifungal compound. The empiric therapy was 
evaluated at 72 hours and nodified or substituted only if the patient had 
not responded, unless adverse reactions or isolation of a pathogen 
resistant to the antibiotic administered in the presence of a deteriorating 
clinical status necessitated an earlier change in therapy.. Daily drug 
administration records were kept by the nursing staff attending the 
patients to document any difference in handling of both formulations of 
ceftazidime, and of local or general reactions to administration of the 
antibiotic. Adverse events were confirmed by the attending physician. In 
general, therapy was continued until the patient had been free of symptoms 
of infection for 4 days, or for 2 days in cases in which the granulocyte 
count had increased to at least 1000/mm. 
Clinical responses were classified as: (a) Success, if all clinical signs 
.and symptoms subsided on the empiric regimen without evidence of infection 
or recrudescence of fever at the time the antibiotics were discontinued, 
nor during follow up; (b) Success with modification, if resolution of 
infection occurred only after addition of other agents to the empiric 
treatment regimen; (c) Failure, if there was no clinical response to 
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initial therapy, even after treatnent modification, and alternative therapy 
had to be given, or death occurred within 72 hours: (d) Unassessable, for 
those cases which proved to be viral or fungal infections, or when a major 
protocol violation occurred, (iicrobiological responses were defined as: (a) 
Success, if the original causative organism was eradicated; (b) Success 
with modification, if the original causative organism could be eradicated 
only after modification ; (c) Failure if cultures remained positive; (d) 
Cases were bacteriologically unassessable for the same reasons as mentioned 
in the clinical definition or if no organism could be isolated. Any 
infection occurring during treatment and not recognized as the initial 
causative organism was defined as a superinfection if further treatnent was 
required. All new isolates without apparent signs of infection and not 
requiring treatment were defined as colonizations. 
RESULTS 
One-hundred patients were included in the study, 50 in each arm. Underlying 
disease, degree of granulocytopenia, mean age and patients of both sexes 
were evenly matched in both study groups (Table I). More patients with 
septicaemia were randomized to CAZ-AfîG. Although localized infections were 
distributed equally between both study groups, more patients with lower 
respiratory tract infection were treated with CAZ-iJA. 
Seven patients in CAZ-fJA group (5 fungal, 1 viral infection and 1 case of 
tuberculosis), and 4 patients treated with CAZ-ARG (2 fungal infections, 1 
case of tuberculosis and 1 non-infectious related death), were unassessable 
for response. Details of the unassessable patients are summarized in Table 
II. 
The results of treatment are shown in Table III with details in 
Tables IV and V. Initial empiric therapy was successful in keeping alive 
98% of the patients treated with CAZ monotherapy, when evaluated after 72 
hours of therapy. One patient died due to a massive gastro-intestinal 
bleeding, not related to his infection, which was already improving. The 
other patient was admitted in shock, due to Corynebacterium parvum 
septicaemia, and died before a second dose of antibiotics could be given. 
Both cases occurred in the CAZ-ARG group. 
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TABLE I 
Clinical data 
Ceftazidime 
Parameter 
Arginine Total 
No. of patients (male/female) 
Mean age (range) years 
Underlying disease (No of patients) 
Acute leukaemia 
Myeloproliferative syndrome 
Malignant lymphoma 
Aplastic anaemia 
Solid tumors 
(Of which patients with bone marrow transplantation) 
50 (27/23) 
45.5 (16-72) 
38 
4 
2 
2 
(9) 
No. of patients with bacterlologica^ly proven infections 27 
Infection sites (No of patients) 
Fever of unknown origin 22 
Septicaemia (secondary) 23 (3) 
Upper respiratory tract 4 
Lower respiratory tract 2 
Skin and aoft tissue 3 
Urinary tract 1 
No of patients with two separate infection sites 2 
No (") of patients with granulocyte count
 3 
at the start of treatment: <• 250/ram 36 (72%) 
250- 500/im' 4 ( B".) 
501-1000/пи' 9 (18") 
>100U/inm' 1 ( 2%) 
50 (24/26) 
43.2 (18-69) 
36 
4 
2 
3 
5 
(6) 
100 (51/49) 
44.4 (16-72) 
74 
8 
4 
5 
9 
(15) 
45 
25 
15 (4) 
1 
13 
1 
_ 1 
36 (72%) 
5 (10%) 
8 (16%) 
ι ( 2·:) 
47 
38 (7) 
5 
15 
4 
1 
3 
72 (72%) 
9 ( 9%) 
17 (17%) 
2 ( 2Z) 
TABLE II 
Unassessable patients. 
Origin of fever Susceptibility Rescue scheme Outcome 
Ceftazidime arginine 
1. Septicaemia: Staphylococcus epidermidis Susceptible 
2. Acute miliary tuberculosis Resistant None 
3· Bronchopneumonia: Candida albicans Resistant 
4· Bronchopneumonia: Candida tropicalis Resistant 
Died on third day, of GI bleeding, 
while signa of infection were improving 
Died on twentieth day. postmortem 
diagnosis· 
Aaphotericin-B Died on fifth day. 
Amphotericin-B Improved· 
Ceftazidime sodium 
1· Pleuritis: Coxsackie-B virus (ARDS) Resistant 
2. Bronchopneumonia: Aspergillus fumigatus Resistant 
3· Bronchopneumonia: Aspergillus fumigatus Resistant 
¿, Bronchopneumonia: Candida albicans Resistant 
5. Bronchopneumonia: Candida albicans Resistant 
6· Bronchopneumonia: Candida albicans + Resletant 
Escherichia coli Susceptible 
7. Bronchopneumonia: Tuberculosis Resistant 
Artificial 
respiration· 
None 
Improved 
Died fourteenth day· Aspergillus 
postmortem diagnosis· 
Amphotericin-B Died on tenth day· 
Miconazole Died on eleventh day· 
Miconazole Improved 
Amphotericin-B Died on eighth day after Streptococcus 
faecalis superinfection. 
Streptomycin, Improved 
rifampicin, INH 
48 
TABLE III 
Results of therapy in assessable patients 
Parameter 
Ceftazidime 
Arginine Sodium Total 
No of assessable patients 
Days of therapy with ceftazidime 
(Mean ± Standard deviation: (range)) 
Clinical outcooe No (%) of patients: 
Cure empiric therapy 
Cure modified therapy 
Failure 
Bacteriological outcome in documented infections 
No (%) of patients: 
Eradication 
Eradication after modification 
Failure 
Bacteriological outcome In septicaemia 
No (%) of patients: 
Eradication 
Eradication after modification 
Failure 
Clinical outcome in bacteriologically undocumented 
infecions No (Z) of patients: 
Cure empiric therapy 
Cure nodifled therapy 
Granulocyte count (Z) of patients at time of response*41 
< 250/mm' 
250- SOO/nm1 
501-1000/ran 
HOOO/rara' 
46 43 89 
9.0 ± 5.0 (0.3-31) 8.7 ± 3.6 (1.5-23) 8.9 ± 4.3 (0.3-31) 
38 (83%) 
7 (15%) 
1 ( 2%) 
26 
21 (81%)* 
4 (15%) 
1 ( 4%) 
21 
17 (81%) 
3 (14%) 
1 ( 5%) 
21 
18 (86%) 
3 (14Γ.) 
It 
25 (66%) 
3 (21%) 
3 ( 8".) 
2 ( 5!.) 
39 (91%) 
4 ( 9%) 
16 
14 (87%) 
2 (13%) 
14 
12 (86%) 
2 (14%) 
27 
25 (93%) 
2( 71) 
28 (72%) 
8 (20%) 
1 ( 3%) 
2 ( 5%) 
77 (87%) 
11 (12%) 
1 ( 1%) 
42 
35 (83%)* 
6 (14%) 
1 ( 3%) 
35 
29 (86%) 
5 (14%) 
48 
43 (90%) 
5 (10%) 
53 (69%) 
16 (21%) 
4 ( 5%) 
4 ( 5Z) 
* Included one clinical unassessable patient. 
** For successfully treated patients. 
Overall CAZ monotherapy was successful in 77% of all cases 
(including assessable and unassessable patients) with a return of 
tenperature and clinical conditions to normal; a further 12% responded to 
additional antibiotics and 2% to antifungal agents. No difference in 
overall results were observed between the sodium and arginine formulations. 
Analysis of the assessable cases showed that 39 (91%) out of A3 patients 
were successfully treated with CAZ-NA alone, and the remainder responded to 
the modified therapy. CAZ-ARG monotherapy was successful in 38 (33%) out of 
46 clinically assessable patients, and a further 15% responded to 
additional antibiotics. 
Forty-two of the 89 assessable patients had bacteriologically docunented 
infections; 35 (33%) of the 42 were cured by ceftazidime alone. Fourteen 
(37%) out of 16 allocated to treatment with CAZ-NA responded to 
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monotherapy: two patients, both with Staphylococci resistant to ceftazidime 
responded after additional treatnent« Twenty-six patients with a 
bacterioLogicalLy proven infection were treated with CAZ-Arg; 21 (31«) were 
cured by monotherapy, and a further 15%' responded to additional antibiotics 
(see TabLe V ) . 
At the time of response the majority of the successfully treated 
patients were stilL profoundly neutropenic. Fifty-three (69%) patients had 
less than 250 granulocytes per mm , and 95% Less than 1000/mm. Doth 
formulations of CAZ were comparable, and did not show any substantial 
increase of the granuLocyte count before response· 
TABLE IV 
Clinical successes after modification and failures of therapy 
Original isolate (Superinfection) Ceftazidime susceptibility Rescue scheme and outcome 
(original/ superinfection) 
Ceftazidime arginine 
Success after modification 
1. Staph, epidermidi s (sputum) 
2. Clostridium perfringcns (blood) 
Staph, aureus (blood) 
3. Staph, epidermidis (blood) 
Corynebacc· parvum (blood) 
4. Strep, viridans (throat) 
Staph· epidermidis (throat) 
(С, albicans (sputum) 
5. Cutaneous phlegmona» no organism Isolated 
6. Fever of unknown origin 
7. Fever of unknown origin 
Failure 
Vancomycin eradicated 
Resistant 
Susceptible (eradicated) 
Penicillin-G + eradicated 
vancomycin 
Resistant 
resistant 
Susceptible (eradicated) 
resistant 
/resistant 
-
Vancomycin 
vancomycin 
Vancomycin 
Itraconazole 
Vancomycin 
Vancqmycin 
eradicated 
eradicated 
eradicated 
died 30th day 
improved 
improved 
improved only after recovery 
of granulocytes. 
1. Corynebecterlum parvum (blood) Resistant Died after first dose 
Ceftazidime sodium 
Success after modification 
1* Staph» aureus (blood) 
2. Enterobacter cloacae (blood) 
Staph* epidermidi s (blood) 
3. Bronchopneunoniai no organism isolated 
4. Fever of unknown origin 
Susceptible (eradicated) 
resistant 
Vancomycin 
Telcoplanin 
Erythromycin 
Vancomycin. 
eradicated 
eradicated 
improved 
improved 
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TADLE V 
Distribution of pathogens and results of therapy by pathogen* 
Organism 
Ceftazidime arginine Ceftazidime sodium 
M M 
5. aureus 
S. epiderojidis 
Streptococcus sanguis 
Streptococcus vindans 
Corynebacterium раг иа 
Campylobacter species 
#. Influenzae 
Klebsiella pneumoniae 
Klebsiella oxytoca 
Enterobacter cloacae 
Pseudooonas aeruginosa 
Clostridium perfringens 
ι 
the 
S - success, M « success after modification, F - failure 
* Unassessable cases are not Included (summarized in Table ! ! ) • 
Four superinfections 
occurred during 
monotherapy. Two in 
both arms/ one 
Streptococcus 
faecalis, and 
Staphylococcus 
epidermidis in 
group treated with CAZ-
NA, and one Strep. 
faecalis plus 1 
Candida albicans 
during CAZ-ARG 
treatment. 
One of the patients 
treated by CAZ-UA 
developed a skin rash. Three patients in each arm showed a transient rise 
in glutamic-oxaloacetic and glutanic-pyruvic transaminases, with a rapid 
return to normal after the end of treatment. Λ positive direct Coombs test 
without evidence of haemolysis occurred in 2 patients treated with CAZ-tJA 
and 1 with CAZ-ARG. None of the patients had any sign of ototoxicity nor of 
nephrotoxicity as measured by serum creatine levels. No local reactions to 
the drugs were seen. Reconstitution of CAZ-NA generated carbon-dioxide and 
preparation of the infusion set was more time consuming in order to avoid 
bubbles entering the line. At times part of the content of the the vials 
was expelled by the raised pressure, generating an offensive odour. The CAZ-
ARG formulation was favoured by the nursing staff because it lacked these 
disadvantages and was considerably easier to handle. 
DISCUSSION 
The success (based on survival) of initial empiric monotherapy with CAZ, 
judged after the first 72 hours of treatment was 98 out of 100. Two 
patients died during the first three days: one died of massive gastro­
intestinal haemorrhage and one of infection associated shock within a few 
hours after admission. [Jone of the established combination schedules could 
have prevented the death of these two patients. All remaining assessable 
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patients were cured by CAZ alone (87%) or after modification of therapy 
(12»). 
Although Gran-positive infections are increasing in neutropenic 
patients ('Jade, et al, 1982), Gram-negative ¡nicroorganisms are associated 
with the highest mortality and failure rate, even in patients treated with 
an adequate antibiotic regimen (Bodey, Bolivar, С Fainstein, 19S2; 
Klastersky, et al, 19o6). No patient with a bacteriologically proven Gram-
negative infection failed to respond to CAZ in this study. Failures in the 
assessable patients were all due to Gram-positive infections and one due to 
an anaerobic pathogen, which is in accordance with in vitro studies 
(Morris, 1985), though it is important to note that S2¡í of all Gran-
positive nicroorganisms were eradicated by CAZ alone, and all initial 
failures responded to modification of therapy. 
Of concern is the increasing group of patients affected with mycotic 
infections of the lower and upper respiratory tract. Only 2 (29%) out of 
seven patients with a mycotic bronchopneumonia survived in this study, 
despite systemic antimycotic therapy. Ноге active antifungal agents will be 
needed to cure effectively systemic mycotic infections. 
CAZ-ARG was as effective as CAZ-MA in this study. Side effects were 
minimal, equal in both groups, and restricted to transient mild elevation 
of liver transaminases in 6% of the patients. This did not interfere with 
the therapy. CAZ-ARG was preferred by the nurses, who found it to be much 
easier to handle and less time consuming in preparation. 
An increase in granulocytes is known to be associated with a better 
outcome (Bodey, Buckley, и Sathi, 1966). In this study, 69% of the patients 
were still severely neutropenic, with granulocytes less than 250/mm at the 
time of response. Only 5% showed an increase over 1000/mm , so this will 
not have been an important factor in the favourable results achieved. 
Vigilance is required when monotherapy is used. Since CAZ was 
introduced in our clinic, five years ago, it has been used as monotherapy 
in over 350 neutropenic patients, and no change in antibiotic 
susceptibility has been observed in the major pathogens affecting these 
patients. Ceftazidime has proven to be a weak beta-lactamase inducer (Neu, 
.1985). Погео ег, even an small inoculum of organisms at the infection site 
tend to systemic reactions in neutropenic patients (Sickles, Greene, S 
Wiernik, 1975). Early intervention with antimicrobial therapy , may 
prohibit the acquisition of stable derepressed mutants. Neither in this nor 
previous studies has induction of resistance been observed, the only 
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faiiures being due to primarily resistant strains. 
In conclusion, CAZ monotherapy is effective and safe for the 
empirical treatment of the febrile neutropenic patient. Ceftazidime 
arginine formulation is as effective and safe as the ceftazidime sodiun 
formulation without the production of the fishy smell and carbon dioxide 
bubbles. 
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CHAPTER 5 
TEICOPLANIN FOR THERAPY OF GRAM-POSITIVE INFECTIONS 
IN NEUTROPENIC PATIENTS. * 
VERHAGEN С. and de Pauw B.E. 
Division of Haematology, Department of Internal Medicine, University Hospital St Radboud, Nijmegen, The Netherlands 
* (Presented : 7th International Symposium on Future Trends In Chemotherapy, 
Tlnenla 26-28 May 1986; will be published by Biosdence Edlprlnt Inc.) 
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SUMMART 
Teicoplanin was evaluated in 20 febrile neutropenic patients as additional 
treatment for suspected Cram-positive infections after inadequate response 
to initial empiric therapy with ceftazidime monotherapy. Five patients with 
primary septicaemia, 3 with secondary septicaemia, 12 with localized 
infections and 3 patients with pyrexia of unknown origin were treated with 
teicoplanin (200 mg bolus iv injection once daily after 400 mg loading 
dose), whilst ceftazidime (2g C> hourly 30 min. infusions) was continued. 
Four patients were unassessable (tbc, viral infection, protocol violation, 
and non infectious pyrexial episode). Clinical cure for the combination was 
achieved in 11 of 16 assessable cases (69/:). Ten of 11 (91',) 
bacteriologically confirned infections were cured after addition of 
teicoplanin. Three strains of Staphylococcus aureus, 4 strains of Staph. 
epidermidis (of which 2 were methicillin resistant), and 3 strains of 
Streptococcus faecalis were isolated from successfully treated patients. 
One patient with /4erococcus and Enterobacter cloacae infection only 
improved after addition of erythromycin. One superinfection occurred with 
signs of interstitial pneumonitis in a patient following bone narrow 
transplantation. .Jeither ototoxicity nor nephrotoxicity occurred during 
treatment. Transient rise of liver transaminases was observed in 4 
patients, but was attributable to teicoplanin in only one case. 
Ue conclude that teicoplanin is a potentially effective and well tolerated 
antimicrobial agent in neutropenic patients with infections due to Gram-
positive organisms. 
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INTRODUCTION 
Early instituted empiric broad-spectrun antibiotic therapy has markedly 
reduced the morbidity and mortality from infections complicating 
neutropenia in patients treated for haer,iatological and other malignane i es. 
Ceftazidime as empiric nonotherapy has proven to be comparable with 
the established combination schedules (1-4), offering the possibility to 
avoid related toxicity (5-o). Like nost combinat ions, ceftazidine hr.s 
restricted activity against Gram-positive microorganisms, and in particular 
has no activity against i.iethici Hin resistant staphylococci and Сгаы-
positive enterococci (9). Although usually less life-threatening than Gran-
negative infections (10,11), the increase of multiresistant Gram-positive 
microorganisms in patients with neutropenia (12) has urged the search for 
potent anti microbi a Is covering these pathogens. No substantial improvement 
was found in two prospective studies comparing combination therapy of 
f lucloxaci Hin (13) or cephalothin (14) plus ceftazidime with ceftazidine 
alone in the empiric treatment of febrile neutropenic patients. Failures in 
aproximatly 5C№ of all Gran-positive infections were mainly due to 
methicillin resistant staphylococci, some non haemolytic streptococci and 
Gran-positve enterococci. These patients were favourably treated with 
vancomycin. 
Teicoplanin is a new glycopeptide antibiotic resenbling the 
vancomycin-ristocetin group (15-17). Its spectrum is restricted to aerobic 
and anaerobic Gram-positive microorganisms (1С). In vitro activity of 
teicoplanin resembles that of vancomycin for staphylococci, but is more 
active against streptococci and enterococci (19). Moreover, the very Long 
half-live of teicoplanin, in excess of 40 hours (20), permits once daily 
administration. A suggested wider margin between toxic and therapeutic 
range in the animal model (21) needs confirmation in clinical studies, but 
may offer an alternative for the well known nephrotoxicity and ototoxicity 
of vancomycin (22,23). In vitro study of the activity of teicoplanin 
against clinical isolates of cancer patients was comparable to that of 
vancomycin (24). In addition, teicoplanin was shown to be effective and 
well-tolerated in Gram-positive infections in patients with various 
underlying diseases (25). 
The present open study was designed to determine the efficacy and 
safety of teicoplanin in febrile neutropenic patients with suspected or 
proven Gram-positive infections, and who were not improving on empirically 
instituted ceftazidine monotherapy. 
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PATIENTS AND METHODS 
This study uas performed at the department of Maematology, St. Radboud 
University Hospital, ..ijnegen. The ¡Jetherlands. All febrile neutropenic 
patients not improving on empirically instituted ceftazidime nonotherapy 
after 48-72 hours, or with a superinfection due to a Gram-positive pathogen 
susceptible for teicoplanin, were eligible for this open study. Inclusion 
criteria for ceftazidinie nonotherapy and grounds for modification have been 
described previously (13). Those patients with a proven infection caused by 
other than Gram-positive microorganisms or pyrexia of non-infectious origin 
were excluded from this study. Also excluded were patients uith a history 
of allergy to vancomycin (26), patients with renal insufficiency 
(creatinine clearance <3ΰ ml/min.), or hepatic failure. 
All patients were nursed in reverse isolation. Pretreatnent 
evaluation included a complete history, physical examination and cultures 
from the blood, urine, nouth, nose, throat, sputum, and any clinically 
suspicious focus. Antimicrobial disc susceptibility testing uas done 
according to the method of Kirby Заиег (27). Discs containing 30 ncg 
ceftazidime and 30 meg teicoplanin were used. A zone of inhibition 14 mm 
was accepted as susceptible (28). Laboratory investigation included 
haemoglobin and haeciatocrit, thrombocyte count, leukocyte count and 
differential, serum creatinine, glutamic-oxaloacetic transaminase, glutamic-
pyruvic transaminase alkaline phosphatase and bilirubin. Urinalysis 
included 24 hr creatinine excretion, protein, glucose content and 
microscopic examination. 
After informed consent was obtained, teicoplanin (200 mg) dissolved in 
sterile water (3 ml) was administered as a slow bolus intravenous injection 
once daily after an initial loading dose of 400 mg. Ceftazidime (2 g 
intravenously every u hours) was continued, and also ketoconzole (200 mg 
once daily orally) or amphotericin-B (400 mg 6 hourly orally) for 
prevention of fungal colonisation. Therapy was usually continued until the 
patient was free of symptoms of infection for 4 days or for 2 days in cases 
in which the granulocyte count had increased to at least 1000/mm. 
Clinical responses were classified as: 
(a) Success, if all clinical signs and symptoms of the principal infection 
subsided without relapse during a follow up period of at least 4 weeks. 
(b) Failure, if there uas no clinical response to the combination 
teicoplanin plus ceftazidime and alternative therapy had to be given, 
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or death occurred after at least A3 hours treatment. 
(c) Cases which later proved to be caused by viral or fungal infections, or 
when the protocol was violated, were classified as unassessable. 
iiicrobiological responses were defined as: 
(a) Success, if the original causative organism was eradicated 
(b) Failure if cultures remained positive. 
(c) Cases were bacteriologically unassessable if no Gram-positive pathogen 
was isolated or if there was a protocol violation. 
Any infection occurring during treatment which was not due to the initial 
causative organism was defined as a superinfection if further treatment was 
required. All new isolates without apparent signs of infection and not 
requiring treatment were defined as colonization. 
The concentrations of teicoplanin were measured in serum samples 
obtained 1 hr. after administration (peak) and inmediately before the next 
dose (through). These measurements were performed on day ^, 2, 4, 7, 10, 14 
and repeated once weekly thereafter. Levels were determined by the standard 
agar well diffusion method, using Dacto Antibiotic iledium ."Ir. 5 (Difco), 
with Bacillus subtilis r.iddlebrook spore suspension (1/2 χ 10 CFU), as the 
test organism. The assay detection limit was 2 mg L . 
Evaluation of the safety of teicoplanin included repetition of the 
laboratory tests twice weekly during and one week after discontinuation of 
treatment, as performed on initiation of therapy. Further cultures were 
obtained during treatment and follow-up period as clinically indicated and 
if suitable specimens were available. Potential ototoxicity was assessed by 
audionetry on the first day of treatment and was repeated once weekly 
during therapy and at follow-up. 
RESULTS 
Twenty patients, 14 men and 6 women, were included in the study. 
Septicaenia and bronchopneumonia proved to be the main infections. Acute 
leukaemia was the underlying disease in 15 patients, a myelodysplastic 
syndrome in 6, and aplastic anaemia in one other. Full details are given in 
table I. 
One patient with a Coxsackie-B vi rus infection and one patient with 
a Streptococcus mitis septicaemia already improving on ceftazidime 
monotherapy, were unassessable for teicoplanin. (Both recovered 
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TABLE I 
C l i n i c a l data on t r e a t e d p a t i e n t s . 
Parai leter 
\o. of patients (men/wonen) 20 (14/6) 
•can a^e J: SD (гапзе) years 45.9 - 17.4 (16) 
Underlying disease λο. of patients: 
Acute leukaenia 13 (65%) 
nyeloproliferative syndrone 6 (30',) 
Aplastic anae.ma 1 ( 5Ό) 
Infection sites No of patients 
Fever of unknown οηςιη 3 (15!=.) 
Septicaenia 5 (25«) 
Upper respiratory tract infection 1 ( 5j) 
Lower respiratory tract infection 6 (30ÎJ) 
Soft tissue infection 3 (15л) 
Urinary tract infection 2 (10..) 
(Secondary septicaemia) (4 20«) 
'Jo of patients with bactenolo^ically proven infections 13 (65/=) 
No (/o) of patients with granulocyte count 
at the start of treatment < 250/mm 9 (45;0 
250- 500/mmJ 4 (207;) 
501-1000/mm1 2 (10 0 
>1000/nim 5 (25") 
successfully) One patient with a combined mycotic and tuberculous 
bronchopneumonia and one patient with a haemhorragic pericarditis without 
obvious infection subsequently died. Both were considered unassessable. 
The results of treatment are shown in table II with full details in 
Table III and IV. Clinical cure was achieved in eleven of 16 assessable 
cases (69%). Two patients with Staphylococcus epiderniidis septicaemia 
showed an initial improvement with lowering of the temperature and 
eradication of the pathogens. But both suffered recurrence of fever and 
despite modification of treatment only improved after recurrence of the 
granulocytes. Although bacteriological successes, both were considered to 
be clinical failures. One patient with bronchopneumonia and negative 
cultures only improved after addition of erythromycin and was suspected to 
have a Legionella Pneumophilia infection. Two patients with soft tissue 
infections only improved after Modification of therapy, (see table III) 
Ten out of 11 (91%) bacteriologically confirmed infections were cured after 
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Table II 
Overall results of "lodified therapy. 
Parametor Results 
¡Io of assessable patients 16 
Days prctreated with ceftazidir.ie 
(¡lean + SD (гап^е)) 3.7 ± 2.1 (1- 9) 
Days of therapy with teicoplanin* 9.6 ± 3.1 (6-17) 
Duration of fever after start teicoplanin (days)* 2.7 ± 1.5 (1- 6) 
Duration of symptor.is after start teicoplanin (days)* 3.9 ± 2.2 (1- 8) 
Clinical outcoiiie ¡ίο (%) of patients: Cure 11 (69«) 
Failure 5 (31 o) 
Bacteriological outcome in docuuented infections 
No ÇA) of patients Assessable 11 
Eradicated 10 (91») 
Failure 1 ( 9л.) 
Granulocyte count (/J) of patients at tine of response* 
< гЗО/пші7 4 (36%) 
250- 500/™ 
501-1000/1 im' 3 (28,1) 
^ЮООЫ-п
3
 Л (36',,;) 
* For successfully treated patients. 
addition of teicoplanin. Three patients with persistent Staphylococcus 
aureus septicaemia (one resistant to ceftazidime and 1 secondary to a 
bronchopneumonia). Four patients had Staph, epidermidis infection, of which 
2 were methiciHin resistant. Three patients with Streptococcus f a e c a l i s 
infections, all of which were resistant to ceftazidime, were cured (See 
Table IV). The only bacteriologically proven infection assed as a failure 
was a patient with an Enterobacter cioacae cultured from a Localized skin 
infection plus i4erococcus septicaenia which only responded to anipicillin 
plus erythromycin. 
One superinfection occurred in a patient with chronic graft-versus-host 
disease after bone narrow transplantation, together with signs of 
interstitial pneumonitis, was considered possibly due to a Cytomegalo­
virus infection. 
По nephrotoxicity was observed. The mean serum creatinine 
concentration before treatment was S6.3 uilol/L, the mean highest value 
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Table III 
Clinical and bacteriological features of patients who failed on teicoplanin therapy 
Сазе Age 
no (yr) 
Infection Organism Susceptibility 
Teicoplanin Ceftazidime 
Rescue scheme and outcome 
2. 
3. 
66 
66 
19 
Cellulitis + 
septicaemia 
Enterobacter cloacae 
¿erococcus 
Bronchopneunonia No pathogen isolated 
Bronchopneumonia No pathogen Isolated 
septicaemia Staph» epxdermidis 
Septicaemia 
Cellulitis 
Staph* epidermidis 
No organise isolated 
Susceptible Susceptible 
Susceptible Susceptible 
Susceptible Résistant 
Susceptible Susceptible 
Erythromycin-eradicated 
Ampicillin-eradlcated 
Erythromycin-improved 
Improved after rise In granulocytes 
Eradicated by teicoplanin 
Eradicated by the combination· 
but second period of fever improved 
only after rise in granulocytea 
Metronidazole plus granulocyte 
transfusions-improved 
observed during treatment uas 83.3 uMol/L and 80.S uIlol/L during follow-up. 
Creatinine clearance was also apparently unaffected the mean values being: 
106 ml/min. before treatment^ lowest nean value 104 ml/rain, during 
treatment, and 113 ml/nin. during follow-up. По proteinuria or glucosuria 
occurred and no abnormalities were found in urinary sediments during 
treatment. 
Table IV 
Isolated pathogens of successfully treated patients 
Case I iicroorganisn 
no· 
Susceptibility 
Teicoplanin Ceftazidime Penicillin Ücthicillin 
1. Staphylococcus aureus + 
2. Staphylococcus aureus + 
3· Staphylococcus aureus + 
4-5. Staph* epidermidis + 
6-7. Staph» epidermidis + 
8-10. Streptococcus faecaJis* + 
+ 
resistant 
+ 
+ 
resistant 
resistant 
not 
+ 
+ 
+ 
done 
resistant 
not done 
+ 
+ 
+ 
+ 
resistant 
not done 
* Susceptible for ampicillin. 
One of the patients complained of a right sided hearing loss after 
finishing an eleven days course of teicoplanin, however further examination 
showed an otitis serosa and his hearing was restored after decongestant 
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Scatterdlagram of changes in hearing sensitivity (¿S) 
by pure tone audiogram before and after treatment 
with teicoplanin. 
nose drops. Figure 1 
shows a scatterdlagram 
of all changes in 
hearing sensitivity 
(¿S) between audiograms 
performed before treat-
nent and during foLLow-
up. The mean change was 
an improvement of 
hearing sensitivity of 
AS 2-4 DD. Попе of the 
patients showed a con­
sistant hearing Loss. 
Four patients showed г 
transient 3-7 fold rise 
of glutamic-oxaloacetic 
transaminase and 
glutamic-pyruvic trans­
aminase. i'lost likely this was due to concurrent reasons in three of them: 
One patient suffered a Coxsackie-B virus infection, one patient was 
concurrently treated with anti-thynocyte globulin, and one with 
erythromycin). The Last patient had a 3 fold rise of both transaminases 
only attributable to the study drug, which returned to nornal after 
teicoplanin was discontinued. 
The concentration of teicoplanin in the sera determined by bioassay 
is shown graphically in figure 2. The mean peak level ± standard deviation 
(and range) was for day 1: 19.9 ± 10.1 (9.3-42.5) mg/L, day 2: 11.2 ± 2.3 
(6.3-16.9) mg/L, day 4: 12.4 ± 3.4 (7.8-20.0) mg/L, day 7: 12.9 ± 3.9 (5.3-
20.0) mg/l, day 10: 16.5 ± 3.1 (10.5-18.3) mg/L and day 14 only one sample: 
17.1 mg/L. The through values were respectivly day 2: 3.0 ± 1.3 ( 2-6.3) 
mg/L, day 4: 4.4 ± 1.6 (2.2-6.7) ng/L, day 7: 5.3 ± 2.3 (2.2-8.8) mg/L, day 
10: 6.3 ± 1 . 8 (3.0-3.2) mg/L and one sample on day 14: 7.3 mg/L. 
DISCUSSION 
The data from this study shows that teicoplanin in combination with 
ceftazidime is an effective and safe drug for the treatment of Gram-
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positive infections in the neutropenic patient. liore than 90% of 
bacteriologically proven Gram-positive infections were cured by the 
combination. In six cases the causative pathogen was resistant to 
ceftazidime and all were eradicated. In the other A cases (2 Staph, aureus 
and 2 Staph, epidermidis all sensitive to ceftazidime) the causative 
pathogens were only eliminated after the addition of teicoplanin. Not all 
patients were neutropenic when teicoplanin was added to the empirically 
instituted ceftazidime monotherapy, which may have contributed to the good 
results obtained. However 64« of the patients were still neutropenic when 
responding to teicoplanin. 
In contrast with the clinical study of Glupczynski et al (25) we saw 
no persistence or recurrence of the pathogens. This difference i.iay be 
partly due to the possible synergistic effect of combined treatment of 
ceftazidime plus teicoplanin. At least the combination may have saved the 
patients from Gram-negative superinfections, which can be rapidly fatal in 
the neutropenic host. 
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Teicoplanin was well tolerated, l.'e did not observe any alteration of 
the renal function, nor could ototoxicity be shown by single tone 
audiometry during treatment or follow-up. A three to seven fold rise of 
transaminases was found in 4 patients, but was considered to be due to 
concurrent hepatotoxic factors in three of then. In one patient a three 
fold transient rise of glutamic-oxaloacetic and glutamic-pyruvic 
transaminase was observed and was most likely due to the combination of 
teicoplanin with ceftazidine. After withdrawal of both drugs a rapid return 
to normal values was seen. 
Based on the results of this study ue conclude that teicoplanin in 
combination with ceftazidime is a safe and effective drug for Gram-positive 
infections in neutropenic patients. 
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CHAPTER 6 
CEFTAZIDIME ALONE FOR TREATING PSEUDOMONAS 
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+ Glaxo Group Research, Greenford, Middlesex, U К 
* (Published "Journal of Infection" (1986) 13, 125-131). 
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SUMMARY 
Twenty nine patients with prinary or secondary hypoplastic bone marrow were 
treated successfully with ceftazidime alone for established septicaemia 
caused by Pseudomonas aeruginosa of which 33% strains were gentanicin-
resistant. All the patients were neutropenic at the start of therapy; most 
were cured with microbiological confirmation before the bone marrow had 
regenerated. One patient died of cerebral haemorrhage due to profound 
throiibocytopenia without evidence of infection at autopsy. Significant 
toxicity was not observed. Ceftazidime alone is, therefore a safe and 
effective treatnent for infections caused by this organisa even in the 
neutropenic patient. 
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INTRODUCTION 
Ceftazidine has a broad spectrun of activity which includes Pseudomonas 
aeruginosa (1,2) ano has been shown to be an effective drug for infections 
caused by this organisn (3-7). In these studies, patients had a wide 
variety of underlying diseases, but experience in treating the neutropenic 
patient, who represents perhaps the ultimate challen^o for any antibiotic, 
is United. Despite its decreasing incidence, Ps. aeruginosa infection 
remains a major threat to the neutropenic host (8). Dortality rates up to 
57/, within 24 hours in neutropenic patients not receiving appropriate 
therapy have been described. If prompt appropriate therapy is begun, cure 
rates of 41.Í to 8υ/« with a mean of 65« may be achieved (9,10). Synergistic 
combinations of either an aninoglycoside plus a beta-lactam antibiotic or 
two beta-lactams have been used to offer the best chance of cure (11). 
Aninoglycosides, however, are associated with side effects particularly 
when given concurrently with agents that potentiate nephrotoxicity (12-14) 
and antagonism between beta-lactans may arise unpredictably. For these 
reasons, single drug therapy may be preferred. As a result of our studies 
of infection inneutropenic patients (15-17), we now have firm evidence that 
this drug provides effective treatment for septicaemia caused by Ps. 
aeruginosa. 
PATIENTS AND METHODS 
Uetween 1931 and iay 19G5, 352 neutropenic patients with febrile episodes 
have been treated with ceftazidime alone or with combinations of drugs as 
empirical treatment in several prospective randomised studies (15-17). 
Their records were reviewed in order to identify those with patients from 
whom Ps. aeruginosa had been isolated from at least one of three samples of 
venous blood taken at different tines from three different sites. All 
patients were profoundly neutropenic at the onset of fever (see Table I ) , 
all were nursed in reversed-barrier isolation and all but three had 
received orally various forms of selective decontamination of the gut. This 
consisted of 960 mg co-triiiioxazole 3 hourly, 100 mg polymyxine-B and 250 mg 
niconazol or 400 mg anphotericin-S 6 hourly. 'Jhen broad-spectrum 
antibiotics had to be started, selective decontamination of the gut was 
discontinued, except of the antifungal compound, and was reinstituted as 
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TABLb I 
Days of fever 
patients with 
Patient 
No. 
1 
2 
3 
4 
5 
6 
7 
β 
9 
10 
11 
12 
13 
14 
15 
16 
17 
ia 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
Days of 
fever 
4 
5 
Э 
6 
8 
2 
6 
8 
15 
3 
3 
2 
12 
1 
2 
4 
16 
4 
3 
11 
9 
4 
4 
4 
4 
1 
1 
20 
2 
, symptoms, therapy ' and neutrophil count of 
ι Pseudomonas septicaemia. 
Days of 
symptoms 
5 
4 
3 
1 
1 
2 
2 
11 
17 
5 
3 
2 
16 
5 
2 
8 
21 
4 
3 
11 
9 
3 
6 
4 
3 
2 
1 
21 
2 
Days of 
therapy 
13 
11 
7 
9 
18 
6 
8 
18 
26 
9 
10 
7 
19 
9 
7 
13 
31 
7 
9 
15 
14 
В 
10 
11 
7 
7 
6 
26 
9 
Neutrophils at (ж li/IL) 
Onset 
0.20 
0.20 
1.00 
0.10 
<0.10 
<0.10 
0.50 
0.20 
0.50 
1.00 
0.60 
0.40 
0.90 
0.40 
0.10 
0.40 
¿0.10 
0.20 
0.10 
0.80 
«0.10 
0.30 
0.20 
0.30 
0.30 
0.70 
0.20 
0.10 
¿0.10 
Resolution 
0.20 
0.10 
2.40 
¿0.10 
¿0.10 
0,10 
0.30 
0.20 
0.50 
0.70 
0.50 
¿0.10 
1.00 
0.20 
0.70 
0.50 
¿iO.lO 
0.40 
0.50 
0.50 
0.10 
0.70 
¿0.10 
0.10 
0.40 
0.50 
0.10 
0.30 
0.50 
soon as the broad-
spectrum antibiotics 
were discontinued. 
Ceftazidime (2g 3 
hourly in a 30 nin 
infusion) was given 
enpirically as soon 
as a patient had 
been febrile 
(temperature > 3o.5 
eC) for 2-5 h. One 
patient received a 
dose of 1Q О hourly 
in order to adjust 
for a pre-existing 
impaired renal 
function. Concurrent 
administration of 
llean 5.76 6.10 12.07 0.33 0.40 f luC l o x a c 1 111П ОГ 
cephalothin was not 
considered ground for exclusion since neither drug is active against Ps. 
aeruginosa. Granulocyte transfusions were not given and patients were 
treated with ceftazidime for 4 days after resolution of fever with a 
minimuci of 7 days treatment. Clinical cure was defined as complete 
resolution of all signs and symptons without evidence of infection at the 
end of therapy or during immediate follow-up. Eradication of the orgamsn 
without recurrence during the subsequent 4 weeks was considered to be a 
satisfactory microbiological response. Full records included a complete 
history, physical examination, chest X-ray and the results of regular 
cultures obtained froin the throat, faeces, urine, sputum and blood. 
Ilaematological (Uenalog D Technicon Instruments, Tarrytown, MY, U.S.A.) and 
biochenical profiles were obtained three times weekly. Strains of Ps. 
aeruginosa were characterised by growth on cetrinide agar at 42 C, 
production of pyocyanin and detection of fluorescein by illumination with 
ultra-violet light. Susceptibility to antibiotics was determined by means 
of the disc-diffusion method of Kirby-Dauer (13). For ceftazidime, zones of 
inhibition of more than 16 nn were classified as susceptible, zones of 
inhibition less than 14 mm as resistant and the remainder as intermediate. 
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RESULTS 
Of 29 patients treated with ceftazidine, nine had received other 
antibiotics concurrently (cephalothin five patients, flucLoxaciHin four 
patients). Five patients were changed to ceftazidime having failed to 
respond to gentanicin plus a cephalosporin. All but four .patients had 
¡nalignant disease of the bone marrow. Of these, 14 were diagnosed as having 
acute myeloid leukaemia. Two of the patients were given alloçjeneic bone 
marrow transplants and both survived. Other details are shown in Table II. 
IJine patients had clinical evidence of tissue infections of which 7 were 
localised in the respiratory tract, five patients having bronchopneunonia. 
TABLE II 
Clinical decs of the patiente with Pseudoaonas septicaemia· 
Patient 
.No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
H 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
Mean 
Аве 
(years) 
29 
43 
37 
29 
18 
40 
16 
35 
34 
22 
48 
16 
49 
58 
60 
63 
40 
49 
38 
46 
39 
71 
31 
56 
64 
37 
15 
64 
73 
42 
Sex 
F 
F 
M 
И 
F 
M 
M 
M 
F 
M 
M 
H 
.1 
M 
F 
F 
M 
H 
M 
M 
M 
F 
H 
M 
il 
M 
F 
M 
F 
Underlying 
disease 
AML 
AML 
AUL 
AML 
AML 
AML 
AML 
AML 
AML 
AML 
AML 
AML 
AML 
AML 
ALL 
ALL 
AU 
ALL 
ALL 
ALL 
LYMPHOMA 
LYMPIOIA 
LYHPIIOMA 
APL.AN. 
APL.AN. 
APL.AN. 
HCL 
ιια Solid T. 
Clinical 
infection 
S 
S 
S+Pharyngitis 
S 
S+Cellulitis 
S 
S+Shock 
S+Bronchopn. 
S+Bronchopn. 
S 
S 
S 
S+Bronchopn. 
S 
S 
S 
S+Cellulitis 
S 
S+Pharyngitis 
S 
S+Bronchopn. 
s 
S+Bronchopn. 
S+Shock 
S 
S 
S 
S 
S 
Previous 
therapy 
SGD 
SGD 
SGD 
SGD 
SGD 
SGD 
SGD 
SGD 
SGD 
SGD 
SGD 
SGD 
bGD+Gent. 
+Ctx. 
SGD+Gent. 
•tCfx. 
SGIMent. 
+Cfx. 
SGD 
SGD 
SGD 
SGD 
SGD 
Gent.+Ctx. 
Gent.+Cthn. 
SGD 
SGD 
SGD 
5GD 
SGD 
SGD 
Additional 
therapy 
4x2g 
4x2g 
4x2g 
4x2g 
4x2g 
4x2g 
Cthn. 
Fluc. 
Fluc. 
Fluc. 
Fluc. 
Cthn. 
4x2g Cthn. 
4x2g 
4x2g 
Cthn. 
Cthn. 
Colon­
isation. 
S.epid. 
S.faec. 
Calò. 
SGD, Selective Gut Decontamination; S, Septicaemia; AML, Acute Myeloid Leukaemia; 
Dronchopn, ВгопсЬорлеилюпіа; Cthn, Cephalothin; Gent, Gentamicin; Ctx, Cefotaxira; 
Cfx, Cefuroxim; ALL, Acute Lymphoblastic Leukaemia; 5.epid, Staphylococcus 
epidermidisi S.faec, Streptococcus faecalísi Fluc, Flucloxacillin; APL.AN, 
Aplastic Anaemia; [KL, Hairy Cell Leukaemia; Calò, Candide albicans ι Solid Τ, 
Solid Tumor. 
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Shock was diagnosed in two patients both of whori presented with 
hypotension, rigors and peripheral vascular collapse. They were treated 
concomitantly with infusions of plasma. One patient died on the óth day of 
treatment from cerebral haemorrhage which was attributed to profound 
thrombocytopenia. Olood cultures had become sterile on 3rd day. Evidence of 
infection was not found post mortem. Clinical cure and complete eradication 
of ^s. aeruginosa were observed in all 29 cases. Blood, sputum and 
mouthwashes became bacteriologically negative; neither colonization nor 
recurrence was observed during surveillance for at least 4 weeks. All 
patients were neutropenic at the onset of fever with a mean neutrophil 
9 
count of 0.33 χ 10 /L. Five patients had an increase of their neutrophil 
о 
count during therapy of more than 0.25 χ 10 /L, but in only one did the 
о 
neutrophil count exceed 1.0 χ 10 /L during this period, neutropenia 
following cessation of antibiotics continued for a mean of A days (range Ο­
ΙΑ days). Patients were febrile for a mean of 5.7 days (range 1-20), but 
their sy.Mptoms were present for longer (mean ó.6 days: range 1-21) and they 
received therapy for a r¡ean duration of 12.1 days (range 6-31). In patients 
with a clinical focus fever took longer to subside than it did in those 
without (median Ζ days vs. 4 days: 0.01<p<0.ü5 Rank Sum test), their 
symptoms persisted lonjer (11 days vs. 3 days: 0.001<ρ<. 0.01) and they 
received significantly more therapy d o vs. 9 days: 0.001 <p<0.01). All 
strains of Ps. aeruginosa were susceptible to ceftazidime compared with 52« 
that were susceptible to gentamicin (Table III). Serious adverse effects 
were not seen during this study. One patient developed a transient moderate 
rise of the serun transaminases, tolerated with continuation of ceftazidime 
TABLE III 
In-vitro Susceptibilities of the strains of 
Pseudomonas aeruginosa isolated 
Antibiotic Susceptible Intermediate Resistant 
Gentamicin 
Tobramycin 
Amikacin 
Azlocillin 
Carbenicillin 
Piperacillin 
Cefsulodin 
Ceftazidime 
N (¡ó) 
15 ( 52) 
23 ( 79) 
23 ( 79) 
17 ( 53) 
17 ( 59) 
18 ( 62) 
21 ( 72) 
29 (100) 
N (%) 
3 (10) 
2 ( 7) 
4 (10) 
6 (21) 
4 (14) 
3 (10) 
-
-
N (S) 
11 (38) 
4 (14) 
2 ( 7) 
6 (21) 
8 (28) 
8 (28) 
8 (28) 
-
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and reversible after the drug was 'withdrawn. Three patients became 
colonized by other nicro-organisns, one with Candida albicans, one with 
Staphylococcus epidermidis and one with Streptococcus faecalis· Drug 
related nephrotoxicity was not registered. 
DISCUSSION 
Before effective therapy was available 16;; of cancer patients with 
septicaemia caused b> Ps, aeruginosa died within the first 12 hours and ZZ',', 
died within a day of the organisn beincj isolated fron the blood (19). The 
sane figures are found today if inappropriate therapy is instituted (10). 
This study clearly deiionstrates the potency of ceftazidime as anti-
pseudomonal therapy even though nost patients were severely neutropenic. 
The average time taken to effect cure was 6 days which is lonyer than many 
protocols allow before modifying therapy, nost patients with unconplicated 
bacteraernia were free of symptoms within 4 days, whereas those in whom 
localised infection was diagnosed required longer treatment. Donnelly and 
colleagues (20) reported similar findings and suggested that in these 
circunstances additional antibiotics night be required to assist in better 
penetration or accelerated killing of bacteria. Since the ultimate outcome 
was excellent in both groups of patients a second antibiotic seens 
unnecessary unless faster resolution of symptoms can be shown. These 
results are better than those obtained fron treating similar infections 
with aminoglycosides. Only in non-neutropenic patients did the success rate 
for gentamicin or tobramycin given alone reach SO'/.. Patients with severe 
neutropenia and a susceptible organism had only a 29% cure rate if treated 
with aminoglycosides alone. Cure rates for an anti-Pseudomonal penicillin 
with or without an aminoglycoside did not differ and reached 72'.i (10,21). 
Single drug therapy for Pseudomonas infections is more effective with 
ceftazidime than with any other single antibiotic. Furthermore, this drug 
results in cure rates similar to those achieved with combinations of other 
antibiotics. 
The choice of drug depends, not only on its proven efficacy but also 
on the antibiotic susceptibility of the pathogens prevalent in the 
particular population of patients. Extensive use of single drug therapy 
requires vigilance since success depends upon continued susceptibility to 
the particular drug. In our experience, emergence of resistance to 
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ceftazidine has not arisen after 4 years of use nor has there been a shift 
in susceptibility patterns of prevalent pathogens. The potential for 
toxicity also influences the choice of antibiotic and becomes of crucial 
importance if it is to be administered with nephrotoxic drugs such as cis-
II-platinur.i or cyclosporin A, both often required to nanage malignant 
diseases or bone marroi; transplant recipients (22). Moreover, as shown in 
this study, neutropenic patients often require prolonged courses of 
antibiotic therapy and aniinoglycoside-related toxicity is generally 
believed to increases with the length and number of courses (23). Further 
studies (24,25) in febrile neutropenic patients also suggest that 
ceftazidime therapy alone is an effective and non-toxic alternative to 
coinüination therapy in the empirical treatnent of the inrnuno-conpromised 
host if one is prepared to nodify therapy should infection by a resistant 
Gran-positive organism arise. Given its safety (26) and efficacy, 
ceftazidine nay be considered as the drug of choice for first-line therapy 
of fever during neutropenia in patients at risk of ototoxicity and 
nephrotoxicity (2,15-17,20,24,25) and should prove highly effective for 
most infections caused by Gram-negative bacilli without the need to nodify 
therapy. 
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SUMMART 
Ceftazidime was used as Monotherapy for 30 febrile episodes in 2C patients, 
who underwent allogeneic bone narrow transplantation and who were treated 
conconitantly with the innunosuppressive agent cyclosporin-Л. Ceftazidime 
did not enhance the well established nephrotoxicity of cyclosporin-Α as 
neasured by serum creatinine levels or creatinine clearance. .Uthough an 
increasing nunber of Gran-positive infections in these patients warrants 
viai lance, ceftazidine as initial enpirical monotherapy proved to be 
successful in 957, of all febrile post-transplantation patients. All Gran-
negative, and 69 Í of the Craii-positi ve infections were cured with 
ceftazidime alone. The overall clinical cure rate was TZli, with 
microbiological clearance in bj ,. This conpares favourably with 
aninoglycoside containing schedules, and avoids the aninoglycoside 
associated nephrotoxicity. 
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INTRODUCTION 
In the last decade, allogeneic bone .narrow transplantation has been shown 
to provide a possibility for curative correction of a number of lethal 
conjenital and acquired disorders of the haematopoietic and lymphoid 
systems (.Mi. Infections and graft-versus-host disease, however, remain 
major obstacles to the success of a bone narrow transplant. Several 
approaches nave been proposed to prevent or treat acute graft-versus-host 
disease. The addition of cyclosporin-A has been a step forward and proved 
even to be associated with a faster engraftnent (6). The major side-effect, 
however, is dose relateo nephrotoxicity (2,7,9,20), which is enhanced by 
important antimicrobial agents such as intravenous amphotericine J (10), 
aninojlycosides (22), and co-trinoxazole (19). In the present study we 
report on the conbination of cyclosporin-Л and ceftazidime, a thira 
generation cephalosporin (12), with activity conparable to the 
aminoglycosides (5,13-15), in febrile bone marrow transplant patients. 
PATIENTS AND METHODS 
All patients, who underwent allogeneic bone narrow transplantation and who 
were treated with cyclosporin-Α, from July 1933 until February 19o5 were 
included in this study. Gone marrow donors were histoconpatible siblings, 
except one patient, who received narrow fron a haplo-identical brother (pt. 
22). All but two were suffering from haenatological malignancies (Table I). 
Transplant conditioning was done as previously described (24). All patients 
were nursed in single rooms with filtered air under positive pressure 
throughout the transplant period. Л И received oral selective gut 
decontamination (ciprofloxacin or pipemidic acid, and amphotericine C ) , 
herpes virus prophylaxis with acyclovir orally, and all females received 
lynoestrenol. Cyclosporin-A was given 3 mg/kg continuously intravenously 
from day -1 to +22 from transplantation, followed by 3x3 mg/kg/day orally 
with a gradual tapering off after eight weeks with 50-100 mg/week and 
discontinuation after twelve weeks. The dose was adj'usted according to 
trough serum levels (400-600 ng/ml) and serum creatinine if necessary or 
after the occurrence of other side effects, such as hepatotoxicity, 
tremors, skin eruptions, hyperaesthesia or gum hypertrophy. Ceftazidime (2g 
3 hourty in 30 min. iv. infusion) was given empirically as soon as a 
23 
patient had becone febrile (tenperature >3L.5 С) for noie than three 
hours. Only one patient got a reduced dose (1g 8 hourly as a 50 min. 
infusion) in order to adjust for a pre-existing renal impairment. 
Pretreatnent evaluation, culturing and follow up was done as previously 
described (13). Three blood cultures uere taken, one hour appart fron 
different sites with 20 cc blood to improve the chance of a positive 
culture. This was repeated as long as a patient remained febrile. Serum 
creatinine levels were followed daily and the urine was exanined for casts 
and protein. Creatinine clearance was calculated from the serum creatinine 
and 24 hours urine creatinine excretion. Haematological (Henalog D, 
Technicon Instruments Tarrytown, NY, USA) and biochemical profiles were 
obtained three times weekly. 
All febrile patients, who received cyclosporin-A after bone narrow 
transplantation and who were treated concomitantly with ceftazidine for at 
least 4J hours were assessable to evaluate toxicity. All patients who were 
treated with ceftazidine for at least 48 hours, including those who changed 
because of therapy failure within that time, were assessable to study the 
efficacy of ceftazidine monotherapy as initial empiric treatment. Failure 
of initial enpiric treatment was defined as mortality due to infection 
within 43 hours after therapy had started and infection related death 
afterwards if another initial therapy could possibly have prevented an 
eventually lethal outcone. Clinical or microbiological success of 
ceftazidime monotherapy was defined as cure without the need of 
modification. A clinical cure was defined as complete resolution of all 
signs and symptoms with no evidence of infection at the end of therapy or 
during immediate follow-up. Eradication of the organism with no recurrence 
during the subsequent four weeks was considered a satisfactory 
microbiological response. A superinfection was defined as any new acquired 
infection during treatment or within 43 hours after finishing ceftazidime 
monotherapy, which then required subsequent therapy. 
RESULTS 
All thirty-eight consecutive transplanted patients who received cyclosporin-
A were eligible for this study. Seven patients never experienced any 
febrile periods. The renaining thirty-one had altogether 33 febrile 
episodes. Three patients were not assessable to evaluate toxicity as 
34 
they received ceftazidine for Less than A3 hours. Tuo of these patients 
died due to a relapse of their Іеикелііа within 2 days after becoming 
febrile. The third patient was reallocated to a combination of cephalothin 
and vancomycin within 24 hours, because the blood cultures showed growth of 
Staphylococcus epidermidis and Streptococcus viridans. Both microorganisms 
however uere later shown to be susceptible to ceftazidime by disktesting. 
Thirty febrile episodes in 23 bone narrow recipients, were therefore 
eligible for toxicity analysis. The age of these patients ranged fron 16 to 
40 years with a mean of 27 years, thirteen were feriales and fifteen nales. 
The diagnosis and denographic details are shown in Table I. 
TABLE ι 
Clinical data of Che transplanted patients with febrile episode(s). 
Patient 
number 
1 
2 
3 
4 
5 
6 
7 
7* 
β 
9 
10 
11 
12 
13 
14 
15 
16 
17 
17* 
13 
19 
20 
21 
22 
23 
2* 
25 
26 
27 
28 
Age 
years 
24 
26 
32 
27 
IS 
21 
16 
,, 24 
17 
19 
22 
30 
30 
34 
40 
22 
40 
·· 37 
37 
16 
36 
21 
18 
39 
32 
30 
17 
25 
Sex 
F 
F 
M 
F 
F 
F 
M 
, F 
F 
H 
11 
F 
F 
F 
H 
H 
11 
. 
M 
F 
M 
M 
F 
M 
M 
и 
F 
(1 
M 
Underlying 
disease 
AIL 
AilL 
AI IL 
AHL 
AUL 
ALL 
ALL 
··· ALL 
ALL 
ALL 
ALL 
ALL 
ALL 
GIL 
CML 
OIL 
OIL 
... 
an 
OL· 
OIL 
on. CML 
CIL 
OIL 
OIL 
Api. An. 
Api. An. 
NIIL 
Clinical 
infection 
Sepsis 
Sepsis 
Sepsis 
Pharyngitis 
Sepsis 
FUO 
Sepsis 
Pharyngitis 
FUO 
Drug Fever 
TBI 
FUO 
AGvIID 
Sepsis 
RIO 
Sepsis 
Sepsis 
FUO 
Sepsis 
Dronchopn. 
Bronchopn. 
Sepsis 
Sepsis 
Sepsis 
FUO 
Sepsis 
Bronchopn.+ 
sepsis 
AGvIID 
Sepsis 
Sepsis 
Isolated 
Illcroorganlsra(s)· 
Streptococcus viridans 
Streptococcus viridans 
Staphylococcus epideraldie 
-Streptococcus viridans 
-
Pseudomonas eeruginosa 
-
-
-
-
-
-
Acinetobacter species 
-Streptococcus sanguis 
Staphylococcus epidermidis 
-Streptococcus viridans 
Klebsiella pneumoniae 
Bacteroides melanogenlcus 
Pseudomonas aeruginosa 
Staphylococcus epidermidis 
Lactobacillus casei 
_ 
Staphylococcus epidermidis 
Staphylococcus aureus 
-
Staphylococcus epidermidis 
Staphylococcus aureus & 
Staphylococcus epidermidis 
Mean 26,7 
* Second febrile period 
AHL- Acute Myeloid Leukemia, AUL- Acute Undifferentiated leukemia, ALL-
Acute Lymphoblastic leukemia, CIL- Chronic Myeloid Leukemia, Api· An.» 
Aplastic Anaemia, NHL* Non Hodgkin Lymphoma, FUO- Fever of Unknown 
Origin, TDI- Total Body Iradlation, AGvIID- Acute Graft-Versue-Ilost 
Disease, Bronchopn«- Bronchopneumonia. 
There was no need to adjust the cyclosporin-Α dosage due to a rise in serun 
creatinine in any individual patient durine] ceftazidine treatment- The mean 
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± Standard Deviation of the levels of the serum creatinine before the start 
of ceftazidine was Gl ± 35 unol/L. (range 44-216). The mean ±SD of the 
highest values during treatment was 33 ± 37 umol/L. (range 45-234), and ten 
days after ternination of ceftazidine 79 ± 35 unol/L. (range 44-222). The 
rnaximum rise of serun creatinine of 13 unol /L. was observed in patient 
17* during a second febrile period when he developed acute graft-versus-
host disease. After high dose corticosteroids a return to the nomai level 
was notea without adjustnent of the drug dosages, iione of the patients 
showed occurrence of casts nor developnent of significant protein loss in 
the urin. The calculated creatinine clearance did neither change during 
therapy (Table II), nor was an enhancement by ceftazidine of other 
potential adverse effects of cyclosporin-Α seen in any patient. 
TABLE II 
Seruci creatinine (and clearance) before, after and maximum levels 
during therapy with ceftazidime and cyclosporln-A concomitantly. 
PATIENT SERUM CREATININE ulIol/L. (clearance ml/rain) 
ilUlBER Pretreatment Peak levels durine FoUou up. 
1 
2 
3 
4 
5 
6 
7 
7* 
8 
9 
10 
11 
12 
13 
1* 
15 
16 
17 
17» 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
54 
72 
56 
47 
53 
62 
63 
79 
56 
48 
55 
72 
100 
132 
140 
92 
125 
89 
216 
90 
104 
44 
58 
64 
71 
80 
88 
79 
75 
57 
91) 
67) 
130) 
130) 
130) 
J28) 
107) 
85) 
90) 
130) 
130) 
130) 
78) 
46) 
49) 
118) 
95) 
94) 
40) 
128) 
51) 
130) 
109) 
130) 
124) 
116) 
130) 
130) 
130) 
130) 
49 
80 
55 
53 
52 
59 
69 
78 
45 
50 
55 
71 
81 
134 
117 
104 
122 
90 
234 
92 
120 
48 
64 
75 
81 
92 
86 
98 
72 
70 
(100) 
( 63) 
(130) 
(130) 
(130) 
(130) 
(124) 
( 93) 
(109) 
(129) 
(122) 
(130) 
( 90) 
( 57) 
( 56) 
(101) 
(103) 
( 78) 
( 39) 
(119) 
( 46) 
(130) 
( 98) 
(121) 
(120) 
(105) 
(128) 
(119) 
(130) 
(130) 
51 
90 
46 
47 
69 
70 
67 
63 
45 
44 
44 
75 
71 
95 
123 
107 
121 
104 
222 
91 
_ 48 
58 
68 
64 
89 
95 
07 
62 
76 
96) 
58) 
130) 
130) 
130) 
99) 
120) 
47) 
109) 
130) 
130) 
130) 
110) 
71) 
39) 
83) 
104) 
38) 
39) 
120) 
- ) 
130) 
109) 
130) 
130) 
102) 
105) 
129) 
130) 
101) 
Mean: 81 (106) 83 (105) 79 (106) 
* Second febrile period. 
Another five patients were not assessable with respect to the 
efficacy of ceftazidime as initial enpiric monotherapy. Two patients 
developed acute graft-versus-host disease with initial temperature rise. 
Ceftazidime was successfully replaced by systemic steroids. One patient had 
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Granulocyte count Nr. (£) of patients 
at onset at response* 
<. гзо/шп 
250- 500/iniDJ 
501-1000/nm-' 
>1СЮ0/іш3 
13 (W%) 
7 (23%) 
3 (10%) 
7 (23%) 
8 ( « : . ) 
3 (17%) 
3 (17%) 
4 (22%) 
* Only successfully treated patients« 
a tenporary tenperature elevation on the second day of total body 
irradiation without signs of infection, or positive cultures. One patient 
had been treated concomitantly with vancomycin and was cured. The fith 
patient was initially treated with vancomycin for a temperature rise after 
bone marrow infusion without success. Ceftazidime was added, but the 
tenperature turned out to be a drugfever. Twenty-five febrile episodes in 
23 bone marrow recipients were assessable. Fourty-four percent of the 
patients had less than 25Ü granulocytes / гел at the onset of fever. The 
same was found at the time they responded to treatment. Three patients had 
a significant rise of neutrophils during treatment. All other had stable or 
decreasing counts 
(Table III). Fifteen TABLE H I 
p a t i e n t s had S e p t i c * Neutrophil count at onset and response of treated patients. 
aemia associated with 
chills, and five had 
localized tissue 
infections ( three 
bronchopneumonia of 
which one associated 
with septicaemia and two pharyngitis). The remainder were suffering from 
fever of unknown origin. The najon'ty of bacterial isolates were Gram-
positive microorganisms (Table I). 
Ceftazidime monotherapy as initial empiric treatment was successful 
in 96:; of all febrile episodes, ilone of the patients died within 48 hours 
due to infection. Two infection-related deaths occurred later. The first, 
patient 21, died with a persisting Staph, epidermidis infection, ó1 days 
after acquiring the infection despite use of different drug combinations. 
The second, patient 19, died on the fourth day due to bronchopneumonia 
caused by Bacteroides melanogenicus although erythromycin had been added 
after 48 hours. Eighteen of the 25 courses (72;;) resulted in a clinical 
cure, and 12 (63%) of the 19 microbiologically proven infections were cured 
with ceftazidime alone. Four patients who failed were rescued by vancomycin 
(nr. 1,16,25 and 27), and one by erythromycin (nr. 22) respectively. 
Failures were not correlated with neutrophil count, nor with tissue 
localisation, but due to infection with resistant microorganisms. The 
median duration of fever was 3 days, as was the median duration of 
symptoms. The nedian duration of therapy was 9 days. Mo colonisation 
occurrecT during ceftazidime therapy, but two patients developed a 
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superinfection. In one patient Staph, epidennidis was cultured 2 days after 
ternination of ceftazidine therapy. He was treated successfully uith 
vancoiiiycin plus cephalothin. The other patient died due to an Aspergillus 
funi-jatus infection despite parenteral ai.iphotericine B. 
Two patients (nr. 9 Ζ 22) experienced drug fever and one of them 
developed an exanthei.iatous rash (nr. 22). All symptoms subsided after 
discontinuation of ceftazidine. 
DISCUSSION 
Cyclosporin-A is widely used as a powerful ifiinunosuppressive agent for 
organ transplantation (4,17) and has an inportant place in the prevention 
and treatment of acute graft-versus-host disease after bone narrow 
transplantation (3,13). Clinical use is hampered by its nephrotoxicity. 
Infections are almost inevitable in bone marrow transplantation procedures 
and even noreso when graft-versus-host disease has occurred (1,11,23). 
Schedules conprisinj aminoglycosides have an established use in the empiric 
treatment of febrile neutropenic patients (3). The combined use of 
cyclosporin-Л and ai/iinoglycosides, however, will be limited by their 
additional nephrotoxicity, but restriction of cyclosporin-Л would endanger 
the patient for developing acute graft-versus-host disease and impair his 
resistance. 
From this study it is evident that ceftazidime is a safe drug with 
no additional nephrotoxicity when used in combination with cyclosporin-A. 
As is already noticed by Pizzo (16) the spectrum of infecting pathogens in 
the neutropenic host is changing to more Gram-positive infections. We found 
comparable results in our study group with 68% Gram-positive isolates. This 
may reflect at least partially the successful selective oral gut 
decontamination, but also partially the increased use of indwelling 
catheters (21). Ceftazidime, an effective drug against aerobic Gram-
negative organisms, is less active in Gram-positive infections. 
nevertheless ceftazidime proved to be a safe drug for initial empiric 
nonotherapy in this study, ilo patient died during initial treatment due to 
infection, and only one infection-related late death would have possibly 
survived if the initial therapy had included drugs with a spectrun 
including anaerobic microorganisms, rone of the established combination 
schedule^, including those containing aminoglycosides, would have prevented 
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this fatality. For 90% of the patients it would not have been beneficial to 
be treated with such a cor.ibination. Clinical cure was obtained in 72% of the 
cases, and an additional 2Ü« after nodification of therapy. All Grar.i-
nerjative isolates and even 09% of the Gran-positive isolates were 
susceptible to and eradicated by ceftazidine alone, '..'ith monotherapy, 
vigilance and continuous Monitorine of the patient is warranted considering 
the possible occurrence or emergence of resistant nicrooyanisi.is. In our 
experience, enerjent resistance to ceftazidime in this particular patient 
population has not occurred after four years of continued use, nor has there 
been a change in susceptibility patterns of prevalent pathogens, üesults of 
ceftazidime as eiipiric nonotherapy in febrile neutropenic patients coñipare 
favourably to two and three drug containiny rejimens (3,5,13-15). Initial 
enpiric therapy with ceftazidine in febrile neutropenic patients is 
advocated when there is no stronj suspicion of Gran-positive infections. 
Tine will be available to await the results of the cultures, saving the 
patient fron the toxicity of combined drug retjinens, especially .jhen 
antibifftics are to be used concomitantly with cyclosporin-A. 
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SUMMART 
The incidence of drug induced skin rashes and related factors were analysed 
in a retrospective study of 151 patients with acute non-lynphocytic 
leukaemia (AüLL). ,iinety-one (óüi.) developed a drug related toxicodermia to 
one or Tiore drugs during renission induction and maintenance therapy. The 
incidence of rashes was ¡nainly confined to the blastic stage of leukaemia 
and occurred significantly less often durine; renission. Patients with acute 
nyeloid leukaenia, FAD classification M , ,2 and ,!5 (i¡1-3) developed skin 
reactions nore often than those of types ¡A and ,.5 С'Л-Ъ"). '„'опеп suffered 
more frequently fron druç induced skin lesions than ¡nen. The incidence of 
drug associated rashes was significantly higher in patients with Л .LL than 
in the general population for: Allopurinol (16);), co-trimoxazole (14;J), 
miconazole (20«), and ketoconazole (loo). The incidence for the penicillins 
(12;;) and cephalosporins ІЪ Л was conforn the upper Unit as reported for 
the general population, /idaitional toxic effects of conoined therapy could 
not explain the differences observed and a dearrangement of tne 
inrnunesystem during the blastic stage of leukaemia is suggested. 
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INTRODUCTION 
An increase in drug related skin rashes has been reported associated with 
viral infections. .Jell known is the anpicillin related toxicodernia in 
patients with Mononucleosis infectiosa (1,2), and co-trir,ioxazole related 
skin rashes in patients with the acquired iniiunodeficiency syndrone (AIDS) 
( J ) . In other diseases with dearrangenent of the inmunesystem like chronic 
lynphatic leukaemia an increase in penicillin allergy has oeen reported 
(4), and an increase of piperacillin related rashes were found in patients 
with acute nyeloid leukaenia (5). 
üy virtue of nore intensive and aggressive chemotherapy it has 
becone possible to induce renission in the majority of patients with acute 
leukaenia. Different neasurements have been introduced to cope with 
conplications due to the considerable suppression of the imnunesyste . after 
chenotherapy. ..ursing in reversed isolation and antibiotics were introduced 
for total decontaMination or selective out decontamination in order to 
reduce the risk of infection, liore drugs are used to support the patient, 
like allopurinol as uricosuricun, antiemetics, tranquillizers, oral 
estrogens to prevent menstrual bleeding in wonen, etc. Patients challenged 
with many drugs have an increased risk of developing toxic or allergic skin 
rashes (ó). 'Je performed a retrospective study to analyse the factors 
influencing the frequency of skin rashes and the chance of occurrence 
related to the different drugs in 151 acute non-lymphocytic leukaemia 
patients (AiJLL). ііоге then fifty percent developed a drug related skin rash 
during remission induction. It appeared that the risk of developing an 
exantherûatic reaction is increased during renission induction. 
PATIENTS AND METHODS 
All newly diagnosed patients with AN'LL adnitted from Januari 1975 till 
Januari 1936 were eligible for this retrospective analysis. Excluded were 
all patients who underwent bone marrow transplantation, as their 
immunologie reactions may be influenced by the donor graft (7). All those 
patients who never completed a remission induction course or died within 10 
days after diagnosis, were excluded also. Leukaemia was classified 
according to the "French-American-British" (FA3) classification. 
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Renission-induction courses were зі еп according to ЕОЛТС protocols and 
evolved fron nonotherapy (1975) to polychemotherapy with cytosine 
arabinoside, adrianycin or daunorubicin and vincristine since 1977. 
Allopurinol as uricosuricun was given in daily doses of 30U ny during 
rem'ssion induction and consolidation courses, üefore 1979 occasionally 
niconazole or co-trii.ioxazole were used as 'jut decontanination. Thereafter 
selective gut decontauination was perforr.ied on a regular base. Polymyxin-3 
(4x 100 ng daily) plus co-trimoxazole (4x 720 ng daily) and miconazole (3x 
500 ng daily) or ketoconazole (200 ng once daily) were used orally. In case 
of adverse reactions, co-trinoxa^ole was replaced by pipimidic acid (4x 200 
ng daily) and the inidazole antifungals by amphothericine-3 (Ax 400 ng) 
orally. Other supportive nedication consisted of Lynestrenol (5 ¡ng daily) 
in all wonen of child bearing age, antiemetics (promethazine-
chloorpronazine or netoclopronide-chloride), and broad spectrun antibiotics 
in case of infection (before 19C1 a broad-spectrum penicillin with an 
aminoglycoside or Cephalosporine; thereafter ceftazidime monotherapy. On 
indication additionally cephalothin, flucloxaciHin or vanconycin were 
added). 
Drug related toxicodennia was defined as all skin rashes, urticaria, 
angioneurotic oeder.ia or fixed eruptions associated with any drug used. The 
najority of patients received multiple therapy. Drugs were withdrawn 
stepswise in case a skin reaction did occur. Λ relation with a certain drug 
was accepted if all signs and symptoms disappeared after withdrawal of that 
particular drug, and/or reappeared after rechallenging with the same drug. 
The incidence of rashes for each individual drug was expressed by the 
percentage of patients exposed to the drug who developed a toxicodernia. If 
more than one drug could be made responsible and no rechallenge was 
performed, then that case was only recorded and not included in the final 
calculations of rash incidence for the individual drugs. 
Incidence of toxicodermia was related to the incidence as reported in 
the literature for non-selected patients (3-16). The influence of age, sex, 
underlying disease, leukopenia, stage of leukaemia, and concomitant use of 
allopurinol was analysed. Statistical nathenatics were perforned with the 
Chi-square test with Yates correction and the Rank-sum test. 
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RESULTS 
Over the period Januari 1975 to Januari 193ó, 193 newly diagnosed patients 
with A.'.'LL were adnitted. Fifteen patients underwent bone narrow 
transplantation and were excluded fron the study. Twenty-one patients were 
not assessable as they died within ID days after adnission or before 
completion of a renission induction course, and 6 patients were lost to 
follow up. One-hundred and fifty-one patients were évaluable. 'Jinety-one 
(00«) developed a drug related toxicodernia during remission induction and 
maintenance therapy. Sixty-four (42;i) against a single drug, 21 (14«) 
against tuo different drugs, 5 (3..) against three and 1 patient (1^) 
against four different drugs. The toxi codemia manifested itself mainly as 
a naculopapular, fine rash and was itching in about half the cases. Often 
the rash became secondary haenorrhagic as папу patients were 
thrombocytopenic at the time of appearance. Less often the skin reaction 
nanifested itself as urticaria, which mainly was associated with the 
penicillins. Angioneurotic edema presented itself only twice, both tii.ies 
associated with co-triiiioxazole. 
Table I 
Drug induced skin reactions in AMLL. 
Incidence drug rashes ¡¡r. reactions/ 
total patients challenged C O . 
During blastic stage of leukaemia S9/151 (59%) 
During leukaenia in remission 12/ 7o (15%) (p< 0.0001)* 
52/75 (69%) 
39/76 (51%) (p< 0.C5) 
* Chi-square with Yates correction. 
The incidence of drug eruptions was higher in women; 52 out of 75 (69%), 
than in men; 39 out of 76 (51%) (p <0.05). «ashes also occurred more often 
in patients with FAD classification .'11, ii2, and i¡3 (¡11-3); 55 out of 7G 
(71%), than patients with ;¡4 and [15 (1,4-5); 36 out of 73 (49%) (p < 0.01). 
The proportion of women was higher in the group ¡11-3 than (14-5, but even 
after correction significantly more patients with ГІІ-3 got a drug 
associated rash. Eighty-nine out of 151 patients (59%) developed a 
toxicodecmia during first renisson induction or during a relapse of the 
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leukaenia. Only 12 out of 73 patients (15.'Л undergoino maintenance therapy 
developed a skin rash. This difference was highly significant (p < 0.0001). 
See table I and II. 
Table II 
Drug induced skin reaclions in Ai'.L and A ' I0L. 
Parameter ¡Jr. of reactions/ patients challenged (/·) 
;,1-3 1.4-5 (Chi-square) 
ilunber of patients 78 73 
i,en/'.;o:,ien 35/43 41/32 (.,3) 
.;ean ago ± SD (range) years 43.4 ± 16.4 (13-74) 44.9 ± 16.0 (15-73) 
Incidence of drug rashes: 
During total follow-up 55/7G (71;:) 36/73 (49/0 
Durine, blastic stage* 54/7o (Ó9;Í) 35/73 (43») 
During renission* 6/41 (15») 6/37 (16íá) 
* Incidence during blastic stage/ 
incidence during renission p< ù.JODI p< 0.001 
Drugs frequently related with toxicodermia in this study were 
allopurinol, co-trimoxazole, niiconazole, ketoconazole, and penicillins, 
less often involved were the cephalosporins. Together these drugs accounted 
for 09;: (111 out of 125) of all drug-associated eruptions. Patients in the 
blastic stage of leukaenia were exposed to a mean of 4.0 of these drugs 
during renision induction. Less often patients in remission were exposed, a 
mean of 2.3 drugs during maintenance therapy. The overall incidence of drug 
eruptions in the blastic stage of leukaemia was 112 during 673 exposures 
(17%) and 13 during 220 exposures (6%) in patients in renission (p* 
0.U0Ü1). Some of these drugs have been studied in nore detail, see Table 
III. 
Allopurinol has been used in 148 patients. Twenty-three (16%) 
developed a skin rash. Eighteen out of 77 (23:.') patients with ¡;1-3 and only 
5 out of 71 (7%) patients with (¡4-5 (p<.0.05). Fifty-three patients used 
allopurinol during naintenance therapy. ¡Jone of these patients in renission 
developed a toxicodermia. :ione of the AiJLL patients treated with 
allopurinol had a notable renal inpairnent. 
One-hundred and forty-eight patients received co-triraoxazole. Twenty 
(14::) developed a skin rash. The incidence was higher in patients with ¡:l-3 
(p< U.J1) 
(p< 0.J5) 
(.JS) 
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Incidence of toxicodermia of some of the most frequent involved drugs. 
Drug Occurring 
during 
Incidence (*.) Incidence/patients challenged Oí) 
General population AHLL total Mt-3 Γ.4-5 
M1-3/M4-5 
(Chi-square) 
Allopurinol Total fol Low-up 
Real ssion-mduct Ion 
Remission 
Relapsed leukaemia 
Incidencer m-generat/ »n AULL 
blastlc stage/ remission 
Co-tnmo*azole Total follow-up 
Remi SSIon-induction 
Remission 
Relapsed Leukaemia 
Incidence: in-general/ m ANLL 
blastic stage/ remission 
Miconazole Total fol Low-up 
Remission-induction 
Remission 
ReLapsed leukaemia 
Incidence: in-general/ In ANLL 
blastic stage/ remission 
Ketoconazole Total foLlow-up 
Remission-induction 
Remission 
Relapsed leukaemia 
Incidence: in-general/ in ANLL 
blastic stage/ remission 
104/2394 (4.3X) 
(Reference 9) 
23/657 (3.5;:) 
(Reference 11) 
23/418 ( 5 . 5 ; Í ) 
(Reference 13) 
10/1361 (0.7%) 
(Reference 14) 
23/14« (16·.) 
18/148 (12» 
0/ 53 -
10/ 55 (16Ï) 
ρ i 0.0001 
ρ < 0.005 
20/148 CHX) 
15/145 (10X) 
1/ 54 ( ZX) 
5/ 49 (10X) 
Pi 0.0001 
ρ < 0.05 
33/1 li, (28;.) 
32/113 (28;:) 
1/ 35 ( У/.ì 
5/ 35 ( Ш . ) 
ρ < 0.0001 
ρ < 0.005 
10/ 57 ( m ) 
4/ 48 ( 8 » 
1/ 26 ( 4Χ) 
5/ 21 (24;'.) 
P i 0.0001 
NS 
18/77 (23%) 
15/77 (19X) 
0/25 -
7/27 (26%) 
ρ « 0.0001 
ρ < 0.01 
12/76 (16·.) 
10/76 (132ί) 
1/29 ( 3%) 
2/23 ( 9%) 
ρ < 0.0001 
I'S 
20/56 (36Х) 
19/53 (36/.) 
1/11 ( 4/.Ì 
3/14 (21%) 
ρ < 0.0001 
NS 
9/37 (24%) 
3/29 (10%) 
1/17 ( 6%) 
5/14 (36;:) 
ρ < 0.0001 
NS 
5/71 ( 7 i ) 
3/71 < 4%) 
0/28 -
3/28 ( И Х ) 
NS 
NS 
S/72 (11%) 
5/69 ( 7;.) 
0/25 -
3/26 (12·.) 
P < 0 . 0 1 
I1S 
13/62 (21·:) 
13/60 (22^) 
0/24 -
2/21 П О « 
ρ< 0.0001 
ρ < 0.01 
1/20 ( 5%) 
1/19 ( 5%) 
0 / 9 -
0 / 7 -
NS 
NS 
( p < 0 . 0 5 ) 
( p < 0 . 0 5 ) 
-NS 
NS 
NS 
-NS 
IJS 
NS 
-NS 
NS 
NS 
-
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twelve out of 76 (1ó/.), conpared to ι.4-5: eight out of 72 (11/'J. During 
remission the incidence was nuch lower: one out of 51 ANLL (2%) (ρ<ΰ.ύ5). 
i.iconazole was used prophylactically in 118 patients. Thirty three 
(23%) developed a rash; ,,1-3: 20 out of 56 (36%), 114-5: 13 out of 62 (21%). 
In contrast only one patient out of 35 (3%) in remission experienced a skin 
rash. This patient with II2 received miconazole intravenously for a 
suspected systemic nycosis. The difference was higly significant (pt 
0.005). 
Ketoconazole as an alternative for miconazole was prophylactically 
used in 57 patients. Ten (13%) developed a skin rash. Only 1 patient out of 
20 (5%) with Π4-5 and 9 out of 37 (24%) with ,11-3. During remission 26 
patients received ketoconazole and one developed a toxicodermia (4%). lione 
of these differences were significant. 
Eighty-nine of the patients received a penicillin derivate. Eleven 
patients (12%) developed a rash. Five during anoxycillin or ampicillin, 2 
during f lucloxaci Hin, 2 during carbenici Hin and 2 during feneticillin 
therapy. None of the rashes was observed during remission. Patients with ¡.1-
3 showed more often a toxicodernia; Seven out of 46 (15%) compared with 4 
out of 43 (9„) in ,.4-5. 
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Four out of 113 (3,)) patients treated with a cephalosporin showed a drug 
related rash. Three during cephalothin, and one during ceftazidine. The 
latter patient had also shown an allergic skin rash to ampicillin on an 
earlier occasion. Incidence of skin rash due to cephalosporins was 
significantly less than due to penicillins (p< 0.001). 
The mean duration of treatnent before occurrence of a drug eruption 
was 3.1 ± Ó.3 days for allopurinol, 11.3 i ó.4 days for co-trinoxazole, 
10.9 ± 6.ó days for niconazole and 9.9 ± 10.7 for ketoconazole. This was 
nuch shorter for the betalactau antibiotics; toxicodermia appeared after a 
mean of 4.7 ± 4.1 days for penicillins and 4.3 ± 2.7 days for 
cephalosporins (p¿.ú.ú01, rank-sum test). 
Incidental drug related toxicodernia was reported for cytarabin 
(3x), iodine (2x), atrphotericine-cJ O x ) , amikacin O x ) , chloorhexidine 
O x ) , cinetidine O x ) , 5-flucytosin O x ) , paracetamol O x ) , ranitidin O x ) , 
rifaiipicin O x ) , and teicoplanin O x ) . 
Λ small group of patients were rechallenged with the sane drug after 
developing toxicodernia. Twenty-seven out of 2r> patients (93,..) showed a 
drug eruption after re-exposure during reriission induction for a relapse of 
their leukaenia. Only 2 out of 20 patients in remission 00«) developed a 
toxicodermia after re-exposure to the sane drug (p< 0.0001). Seven other 
patients with a drug allergy who had not shown any drug eruption after re-
exposure during maintenance therapy, got a full blown toxicodernia again 
after relapse of their leukaemia. 
The incidence of drug induced skin eruptions was not related to age 
or degree of neutropenia. 
DISCUSSION 
Incidence of toxicodermia in the general population is 1-3% (17). In this 
analysis it becane clear, that drug related skin rashes more often occurred 
in patients with A.'iLL. This was mainly due to the high incidence in 
patients with ¡ìl-З. ііогео ег this difference was established to be 
restricted to the blastic stage of the leukaemia. This may explain the 
clinical observation of changing sensitivity to drug induced rashes in 
individual patients. Striking is the identical clinical observation for 
patients with certain viral infections, like mononucleosis infectiosa, who 
also may show an increased drug sensitivity only during the active phase of 
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the infection. The innunological basis for this phenomenon is lacking (17). 
The sane relation was found for some of the known allergenic drugs 
that has been analysed separately. The incidence of allopurinol related 
skin rashes in the general population is 2-5'/, (3,9), the incidence for [,1-3 
during remission induction was 25'/. in this study (p < 0.0001), but normal 
during renission. Although an increase in allopurinol related skin rashes 
in patients with renal failure has been reported (10), this could not 
explain the difference observed as none of the ANLL patients had a notable 
renal impairement. 
The incidence for co-trimoxazol related skin rashes at random is Î-
4/. (11). This is significantly less than the 16^ occurrence in ¡:1-5 (p< 
0.0001) and 11« in r,A-5 (р<0.01). Only in patients with AIDS an increased 
incidence has been reported (3). « 
Skin rashes up to 25.Í have been reported after exposure to Miconazole 
intravenously (12). In orally treated patients the incidence of 
toxicodermia is rare. Heel et al (13) report an incidence overall of Ъ-о^. 
This was significantly less than the incidence in both ii1-3 (36:J) (p< 
0.0001) and І1А-5 < 2 Ш (ρ < 0.0001) 
Incidence of ketoconazole induced rashes in the general population is less 
than Y.'. (14) In patients with AiJLL toxicodermia occurred in 13% of the 
patients exposed to this drug (p <. 0.0001). 
In this study the penicillins and the cephalosporins showed predominantly 
an urticarial rash, which mainly has been associated with Type I allergic 
reactions and IgE antibodies. The use of these compounds was associated 
with an allergy incidence comparable to the higher limit found in the 
general population (15). And, also in contrast with the previously analysed 
drugs, a significantly shorter incubation period was found before a rash 
occurred. An increase of anpicillin related skin rashes was shown in 
patients treated concurrently with allopurinol (16). None of the patients 
in this study was treated simultaneously with allopurinol and anpicillin. 
Toxic influence of concurrently used allopurinol does not explain 
this phenomenon, as only one quarter of the rashes occurred during 
allopurinol treatment. Besides, allopurinol was also employed in patients 
in remission and no increased rash incidence was found during maintenance 
therapy. Analysis of the toxic influence of combined treatment during the 
blastic stage of leukaemia showed that the risk of drug induced rashes was 
33% in case two drugs were used concurrently, and 48% in case of triple 
treatment with known allergenic drugs. This difference explains itself by 
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unrelated addition of chances. Ilultiplication of toxicity in combined 
treatment during blastic stage of leukaenia cannot be the sole explanation 
of the difference found between the rash incidence during remission 
induction or during .naintenance therapy of leukaemia. 
An increased sensitivity (18) or imbalance of the imnunesystem 
during the active phase of leukaemia could possibly acount for the 
differences observed (19, 20). Disruption of this ballance by the 
cytostatic therapy as uatz found in a mouse model (19) cannot be the sole 
explanation of this phenonenon. lie could not prove a relation between 
leukopenia and toxicodennia incidence. Moreover, significantly less 
exanthema occurred during remission, although the same drugs were used for 
consolidation as were used during remission-induction. 
To explain the discordance between 111-3 and !lA-5, one has to accept 
a difference in dearrangement of the cellular immunesystem between these 
two forms of AÍILL. It is tempting to speculate about a modulating role of 
the nonocytoid cells in the acute nyelononocytic or nonoblastic leukaenic 
subsets. The sane acounts for the distinction between sexes. 
The results of this retrospective analysis have made clear that 
there is an increased risk of drug induced toxicodermia in ANLL. This 
increased risk is mainly confined to the blastic stage of leukemia and more 
increased in women and patients with iil-3. 
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SUMMARY 
A retrospective analysis of the results of ceftazidime Monotherapy (CAZ) 
for 284 febrile episodes in neutropenic patients is presented. For 
infections with a known focus the clinical cure rate of secondary 
septicenia (S-SEP) was 73% (n=47); of the upper respiratory tract 
infections (UI!TI) 9^7. (n=29) and of the lower respiratory tract infections 
(LRTI) 34',' (n=76) with monotherapy. The results in skin and soft tissue 
infections (SSTI) and in urinary tract infections CUTI) were 65% (n=23) and 
SS« (n=3) respectively. Only in SSTI was nodification of therapy necessary 
significantly more often than in infections without clinical focus (p 
0.01). Patients with localized infections required prolonged treatment in 
comparison to patients with fever of unknown origin or primary septiceraia: 
a pean of 11 days compared to a mean of 9 days (p<0.0001). Despite a rising 
incidence of Gran-pos-itive infections in neutropenic patients in general, 
the majority of pathogens in bacteriologically proven LRTI and UTI remained 
Grar.i-negative (66 and 80« respectively), whereas the overall incidence of 
Gram-negative infections was 44% in this study. Systemic mycotic infections 
were mainly associated with URTI (34%) and LRTI (21%). It is concluded that 
CAZ is an effective drug for the empiric treatment of febrile neutropenic 
patients with a localized infection, though subsidence of signs and 
symptoms takes longer than in patients without focus. 
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INTRODUCTION 
Profound alterations in the host defences of cancer patients, due to the 
underlying malignancy or secondary to aggressive myelosuppressive therapy, 
have increased the risk and severity of infectious complications. Early 
mortality in febrile neutropenic patients has been reduced mainly by prompt 
institution of broadspectrum antibiotics. After the introduction of the 
combined use of an aninoglycoside with carboxypeniciI Lin, the therapeutic 
arpiamentarium has been expanded and regimens of either a beta-lactan with 
an aminoglycoside or a double betalactam combination have been tested in 
clinical trials during the last decade. In addition to extension of 
antimicrobial spectrum, higher Levels of serun bactericidal activity have 
been achieved accompanied by a better clinical outcome if the antimicrobial 
agents acted synergistically in the combination (1,2). Overall efficacy 
rates of 49-30" have been demonstrated in these patients. However, less 
favourable réponses were obtained in localized infections: cure rates of 23-
63% in lower respiratory tract infections and 0-71% in secondary septicemia 
have been reported (3-12). 
The newly developed third-generation cephalosporins have a broad 
spectrum of activity. Although less active in vitro against Gram-positive 
microorganisms than earlier compounds, they show remarkable activity 
against Gram-negative pathogens (13). With ceftazidime alone serum levels 
exceeding 40-250 times the minimum bactericidal concentration of most Gram-
negative bacteria could be achieved in neutropenic patients (14-16), 
offering the possibility of monotherapy (17,13) which would avoid the 
toxicity (19,20) of various combination schedules (6,8,21,22). 
We have assessed the role of ceftazidime monotherapy in several 
prospective randomized trials and the results compared favourably to 
established combination schedules (23-26). Analysis of Pseudomonas 
aeruginosa septicemia's in these patients showed that the cure rate was 
unaltered in localized infections, but patients with primary septicemia 
only had a faster resolution of symptoms and needed a shorter duration of 
therapy than those with septicemia secondary to a known focus (27). This 
retrospective analysis uas performed to define the possible role of 
ceftazidime monotherapy in neutropenic patients with localized infections. 
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PATIENTS AND METHODS 
Between January 19G1 and January 1986 four clinical trials were conducted 
in order to assess the efficacy and safety of ceftazidime monotherapy in 
febrile neutropenic patients (23-26).All febrile episodes treated with 
ceftazidine monotherapy, in which a localized infection was demonstrated at 
that time have now been reanalyzed separately. Entry criteria, pretreatnent 
evaluation, and follow up for the trials have been described previously 
(24). The empiric therapy was evaluated at 72 hours and modified only if 
the patient did not respond clinically, unless adverse reactions, isolation 
of a pathogen resistant to ceftazidime, or a deteriorating clinical status 
urged an earlier change of therapy. Therapy was in general continued until 
the patient was free of symptoms of infection for 4 days, or 2 days in 
cases when the granulocyte count increased to over 1000/mm . 
Upper respiratory tract infection (URTI) was diagnosed in cases where the 
patient had fever, complained of a sore throat or mouth, and showed signs 
of mucositis not related to previous cytotoxic treatment. Sinusitis and 
otitis media were included in this «jroup of patients. The diagnosis of 
lower respiratory tract infection (LRTI) was based on the presence of 
fever, and at least one of the symptons: cough, sputum production, dyspnoea 
and/or physical signs of pulmonary consolidation or a positive chest X-ray. 
Patients with fever and local tendernes, swelling or erythema, sometimes 
fluctuation, exsudation or ulceration as clinical manifestation of an 
infection of the skin or underlying tissues were diagnosed as skin and soft 
tissue infection (SSTI). All patients with fever and positive urine 
cultures (>10 microorganisns/ml) were considered to have an urinary tract 
infection (UTI). The clinical and bacteriological responses of these 
infections were compared to the results of the treatment of infections 
without a focus for all patients entered into the above mentioned 
randomised trials. 
Antibiotic responses were clinically classified as: (a) "success", if all 
clinical signs and symptoms subsided without evidence of infection or 
recrudescence of fever at the time ceftazidime was discontinued, nor during 
follow up; (b) "success with modification", if ceftazidime was continued 
but resolution of infection occurred only after addition of other agents; 
(c) "failure" if there was no clinical response to ceftazidime alone, nor 
after treatment modification or death occurred within 72 hours; (d) 
"unassessable" classified were all those cases which proved to be viral 
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or fungal infections or in case feve^r was proven to be of non-infectious 
origin, ilicrobiologi'cal responses i;ere defined as: (a) "success", if the 
original causative organism was eradicated by ceftazidime alone; (b) 
"success with modification", if only after additional treatment the 
original causative organism could be eradicated; (c) "failure" if cultures 
remained positive despite modification of therapy; (d) "unassessable" cases 
were as mentioned in the clinical definition supplemented by those for 
which no organisn could be isolated. Any infection by a microonjanisn 
occurring during treatment, not recognized as the initially causative 
organisn and requiring treatment, was defined as superinfection, flew 
isolates without apparent signs of infection were defined as colonizations. 
RESULTS 
Fron 1981 until 1936, ceftazidime monotherapy was empiricaLLy instituted in 
284 patients. The underlying disease was a hematological malignancy in the 
majority of patients (υΰ%); 14% of the total developed fever during bone 
marrow transplantation. More males (161) than females (123) were allocated 
to ceftazidime monotherapy during this period. Other details are shown in 
Table I. 
Tabel I 
Ceftazidime Monotherapy in Neutropenia; Clinical Data. 
Parameter 
No. of patienta (male/female) 284 (1Ó1/12J) 
Mean age ± Standard deviation, (range) years 41.1 ± 16.5 (14-75) 
Underlying disease (No of patients (2): 
Acute leukemia 189 (67%) 
Myeloproliferative syndrome 47 (17») 
Malignant lymphoma 12 ( 4 0 
Aplastic anemia 15 ( 5%) 
Solid tumor 20 ( 7^) 
(During bone marrow transplantation 41 - ) 
Infection localization: 
-Without Focus: Fever of Unknown Origin 
Primary Septicemia 
-With Focus*; Upper Respiratory Tract Infection 
Lover Respiratory Tract Infection 
Skin and Soft Tissue Infection 
Urinary Tract Infection 
(Secondary Septicemia 
* No of patients with two separate Infection sites 
81 
77 
29 
76 
23 
8 
47 
(29,) 
(27;.) 
(101) 
(27Ό) 
( a.) ( 3,.) 
- ) 
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Thirty-six out of 284 patients were considered to be unassessable due to 
mycotic (24) and viral infections (4), tuberculosis (2) and other reasons 
(6) (Table II). 
Tabel II 
Unassessable Patients 
No Focus Focal site Total 
Origin fever FUO P-SEP URTI LRTI patients 
Tuberculosis 1 (1)* 1 2 ( 1 ) 
Fungal infection 1 10+ 16 (9)+ 24 ( 9)+ 
Viral Infection 2 (1) 1 1 * ( 1) 
Drug fever*· 5 5 
Total body iradiatlon 1 1 
Total unassessable 7 (1) 3 (1) 11+ 18 (9)+ 36 (11)+ 
FUO - Fever of Unknown Origin, P-SEP - Primary septicemia, URTI - Upper 
Respiratory Tract Infection, LRTI - Lower Respiratory Tract Infection. 
* (No.) unassessable patients who died. 
+ Three of the systemic mycotic infections were localized in the upper 
and lower respiratory tract. 
** Attributed to earlier instituted cephaloridine gargle (1), cytarabinoaide 
(1), and antl-thymocyte globuline (3) 
The clinical cure rate of ceftazidime monotherapy in the 248 assessable 
patients was 201 (81%). Thirty-five patients (14%) improved after 
modification of therapy and 12 patients (5%) failed despite modification. 
Bacteriological eradication was achieved in 133 (82%) out of 163 strains 
treated with ceftazidime alone. A localized infection with or without a 
septicemia was diagnosed in 126 out of 284 patients. Foci of infection were 
URTI in 29 (21%), LRTI in 76 (56%), SSTI in 23 (17%) and UTI in 3 (6%) 
patients. Ten patients had more than one localized infection at the onset 
of fever, and 47 developed bacteremia secondary to a known focus. Table III 
shows the details of the clinical infections. Relatively more males than 
females suffered a localized infection compared with the ratio in patients 
without known focus. This difference was significant for LRTI (p<0.05). The 
mean age of patients with LRTI and UTI (47 and 46 yrs.) was higher than 
that of patients with an URTI (34 yrs.). LRTI accounted for 48% of all 
infections in patients over 60 years which was 5 times the incidence of 
bronchopneumonia in the age group of less than 20 years. In contrast, URTI 
mainly occurred under 30 years of age. 
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Table III 
Clinical data and Results of Therapy in Localized Infections* 
Results 
No of patients(!i!ale/female) 
Меал age (range) years 
Isolated pathogens 
None 
Single pathogen 
Multiple pathogens 
FUO 
81 (40/41) 
40 (16-74) 
80 (99%) 
1 ( 1%)+ 
P-SEP 
77 (39/38) 
39 (15-72) 
72 (94%) 
5 ( 6%) 
S-SEP 
47 (32/15) 
40 (15-70) 
32 (68%) 
15 (32%) 
URTI 
29 (16/13) 
34 (15-69) 
3 (10%) 
20 (69%) 
6 (21%) 
LRTI 
76 (50/26) 
47 (15-75) 
21 (28%) 
44 (58%) 
11 (14%) 
SSTI 
23 (16/7) 
40 (16-68) 
6 (26%) 
12 (52%) 
5 (22%) 
UTI 
В (5/3) 
46 (30-68) 
6 (75%) 
2 (25%) 
Secondary septicemia** - 13 (45%) 24 (32%) 12 (52%) 5 (63%) 
Clinical cure overall 67 (82%) 54 (70%) 29 (62%) 17 (59%) 47 (62%) 15 (65%) 7 (88%) 
No of assessable patients 
Clinical cure 
Cure with modification 
Failure 
No of isolates 
Bacteriological success 
Success with modification 
Failure 
74 
67 (91%) 
7 ( 9%) 
74 
54 (73%) 
11 Í15%) 
9 (12%) 
82 
61 (74%) 
12 (15%) 
9 (11%) 
40 
29 (73%) 
11 (27%) 
56 
44 (79%) 
12 (21%) 
18 
17 (94%) 
1 ( 6%) 
19 
17 (89%) 
2 (11%) 
58 
47 (84%) 
8 (11%) 
3 ( 5%) 
47 
44 (94%) 
3 ( 6%) 
23 
15 (65%) 
8 (35%) 
23 
16 (70%) 
7 (30%) 
8 
7 (88%) 
1 (12%) 
10 
9 (90%) 
1 (10%) 
FUO - Fever of Unknown Origin, P-SEP - Primary Septicemia, S-SEP - Secondary Septicemia, URTI · Upper Respiratory 
Tract Infection, LRTI - Lower Respiratory Tract Infection, SSTI - Skin and Soft Tissue Infection, UTI - Urinary 
Tract Infection. 
* Total patients entered are 284; 10 patients had more than one localized infect and 47 patients had septicemia 
secondary to a localized infection, hence the total of the Collums is 341. 
+ 'dlialre tuberculosis; post mortem diagnosis. 
** Secondary septicemia occurred in 7 patients with more than one localired infection. 
Clinically proven infections. 
Clinical cure with ceftazidime monotherapy was achieved in 17 out of 29 
(59») patients with an URTI, in 47 out of 76 (62%) with LRTI,™ 15 out of 
23 (65%) with SSTI, and in 7 out of 8 (88%) with UTI. The overall clinical 
cure rate of the assessable cases with a localized infection was 80% (Table 
III). Modification of therapy was successful in all patients with URTI, 
SSTI, and UTI. Failures occurred in 3 out of 58 (5%) patients with LRTI. 
One patient with a pneumonia, caused by Klebsiella pneumoniae and 
Escherichia coli, died on the 4th day of treatment of a myocardial 
infarction; postmortem cultures appeared to be negative. The other 2 
patients died, on the 8th and 21th day of treatment respectively, in spite 
of salvage therapy with am'kacin and amphotericin-B. During the course of 
the disease no pathogens were isolated. 
Microbiologically proven infections. 
The infective agent was isolated from all 8 UTI cases and from 90% of the 
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FIGURE 1 
INCIDENCE OF PATHOGENS IN 284 NEUTROPENIC PATIENTS 
INFECTIONS WITH AND WITHOUT FOCUS. 
H 
о 
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29 URTI cases. In LRTI and SSTI cultures were positive in less than 75/Í of 
the cases. Multiple pathogens were isolated more frequently from patients 
with localized infections than from patients with a primary septicemia (p<. 
0.U5, Table III). Firjure 1 and Table IV show the distribution of the 
raicroorganisas in Localized infections. The majority of infections in URTI 
were caused by Gram-positive bacteria, followed b^ fungi as the second 
major pathogen. In contrast. Gram-negative microorganisms were twice as 
frequently isolated in LriTI than Gram-positive pathogens or funji. Also in 
UTI the majority of pathogens were Gram-negative. In SSTI both Gram-
positive and Gram-negative organisms were evenly involved as causative 
pathogen. The bacteriological clearance rate for assessable patients was 
95% in URTI, 90% in LRTI, 70% in SSTI, and 90% in UTI. 
Tabel IV 
Dis tr ibut ion of Pathogens in Localized I n f e c t i o n s and Resul ts of Therapy. 
Organism P-SEP URTI LRTI SSTI UTI T o t a l * 
S F S F S F S F S F S F 
Gram-positive microorganism 
Staphylococcus epidermidis 
Staphylococcus aureus 
Streptococcus virldans 
• Beta-haemolytlc streptococci 
Streptococcus sanguis 
Streptococcus faecalis 
Streptococcus pneumoniae 
Corynebecteriua раг ит 
Diphtheroids 
Gram-negative microorganisms 
Pseudomonas aeruginosa 
Escherichia coll 
Klebsiella species 
¡laeoophilus influenzae 
Enterobacter cloacae 
Proteus mirabilis 
Campylobacter apecies 
¿clnetobacter species 
Citrobacter freundii 
Anaerobic microorganiam« 
Clostridium perfrlngens 
Anaerobic apeciea 
P-SEP - Primary septicemia, URTI - Upper Respiratory Tract Infection, LRTI - Lower 
Respiratory Tract Infection, SSTI - Skin and Soft Tissue Infection, UTI - Urinary Tract 
Infection, S • Success, F « Failure 
* Organisms isolated from more than one localized infection In the same patient were 
counted once in the colluro "Total". 
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8 
15 
2 
3 
5 -
3 -
30 -
13 -
1 -
5 -
5 -
4 -
1 -
1 -
64 26 
4 2 
- 3 
- 1 
- 2 
- 1 
69 2 
30 -
β 2 
9 -
8 -
7 -
3 -
2 -
1 -
1 -
- 1 
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Table V 
Granulocytes Before Treatment and at Time of Response* 
Neutrophils Fever without Focus Localized Infection 
Start Response Start Response 
< 250/™^ 104 (66%) 73 (60%) 76 (61%) 34 (42%) 
250- SOO/mm* 29 (18%) 33 (27%) 23 (18%) 26 (33%) 
SOl-lOOO/m' 23 (15%) 9 ( 8%) 20 (16%) 15 (19%) 
>1000/.nn1 2 ( 1%) 6 ( 5%) 7 ( 5 % ) 5 ( 6%) 
* For successfully treated patients 
Sixty-four percent of all febrile patients had less than 250 
granulocytes/mm at the start of treatment. At the time of response 95% 
still had less than 1000 yranulocytes/mm3(Table V). 
Duration of treatment was recorded in all successfully treated 
patients as well as the time to resolution of pyrexia and symptoms (Table 
VI). In patients without a focus of infection, the mean duration of 
treatment was G.Ç days with a range from 5 to 20 days, the mean time before 
normalization of the temperature was 3.6 days and before resolution of 
symptoms 2.9 days. The patients with localized infections in general 
required longer treatment with a mean of 11.1 days (6 ± 51, ρt0.0001). 
Likewise a longer persistance of pyrexia was observed with a mean of 4.6 
days (p< 0.0001) and a mean of 5.4 days before resolution of symptoms 
occurred (pt 0.0001). An exception were the patients with UTI, they had a 
quick resolution of pyrexia (3 days) and symptoms (2.3 days). 
Tabel VI 
Duration of Therapy« Fever and Symptoms in Localized infections 
Infection Therapy (days)* p** Fever (days)* p** Symptoms (days)* p** 
No focus 8.9 ± 3.0 (5-20) 3.6 ± 1.7 (1-17) 2.9 ± 1.9 (1- 9) 
FUO 8.7 ± 3.2 (5-20) 3.4 ± 1.5 (1- 7) 2.7 ± 1.8 (1- 9) 
P-SEP 9.2 ± 2.7 (5-17) 3.8 ± 2.0 (5-17) 3.1 ± 2.1 (1- 9) 
With focus 11.1 t 5.6 (6-51) p<O.0OOl 4.6 ± 2.8 (1-16) piO.OOOl 5.4 ± 4.0 (1-40) piO.OOOl 
S-SEP 11.3 ± 5.7 (6-31) рчО.ООЗ 4.7 ± 3.3 (2-15) p<O.0O5 5.2 ± 4.2 (1-17) p<0.0001 
m m 8.8 ± 2.7 (6-15) ns 3.9 ± 1.4 (2- 6) p<0.03 4.2 ± 1.3 (2- 7) p.0.0001 
LRTI 11.1 ± 4.9 (6-31) p.0.0001 4.7 ± 3.1 (1-15) p<0.OOO4 5.8 ± 3.5 (2-17) p.0.0001 
SSTI 13.3 ± 10.7 (7-51) p.0.006 5.5 ± 3.6 (2-16) p<0.003 6.5 ± 10.3 (1-40) p.0.002 
ITTI 10.3 ± 4.1 (9-19) ns 3.0 ± 2.1 (1- 8) ns 2.3 ± 0.9 (1- 3) ns 
* mean ± standard deviation and (range). 
** Wilcoxon test. 
FUO · Fever of Unknown Origin, P-Sep - Primary Septicemia, S-SEP = Secondary Septicemia, URTI -
Upper Respiratory Tract Infection, LRTI - Lover Respiratory Tract Infection, SSTI m Skin and 
Soft Tissue Infection, UTI - Urinary Tract Infection. 
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DISCUSSION 
At initiation of therapy, localized infections could be found in 44% of the 
patients. The overall clinical cure was substantially inferior in upper and 
lower respiratory tract infections in comparison to all other cases. 
Analysis showed that this difference nay be explained by an increased 
incidence of fungal infections. Clinical cure rates in assessable patients 
with and without a clinical focus were similar. In contrast to the 
increasing incidence of Gram-positive infections in immunocompronised 
patients, which has been reported in the literature repeatedly (23-3Ü), the 
majority of infections in patients with LRTI and UTI were caused by Gram-
negative pathogens. Sickles (31) in 1973 and Bodey (32) in 1973 reported 
the same high incidence of Gram-negative pathogens in LRTI; hence a shift 
of causative pathogens in these infections during the last decenium seens 
less obvious. Except for fungal infections in URTI, the distribution of 
Gram-positive and negative organisins was equal in both URTI and SSTI. 
Patients with pharyngitis were mainly affected by streptococci susceptible 
t.o ceftazidime. In SSTI the major infecting pathogen proved to be 
Enterococcus faecalis , which is never sensitive to ceftazidime, or 
Staphylococcus epidermidis. The latter was mainly associated with 
intravenous lines and about half of the strains were sensitive to 
ceftazidime. Patients with SSTI needed modification of therapy more 
frequently (35л), (p¿.0.01), whereas the majority of assessable patients 
with URTI, LRTI and UTI were cured by ceftazidime alone. 
The efficacy of aminoglycosides, especially when tissue invasion 
occurs, is questionable. Only the use of synergistic combination treatment 
may circumvent this problem (33). From the present study it appeared that 
the efficacy of ceftazidime to eradicate a pathogen was not influenced by 
tissue localization of an infection; bacteriological clearance was usually 
achieved when the isolated organism demonstrated in vitro sensitivity. 
Although the eventual cure rates of localized and non-localized infections 
were similar, some obvious differences were observed. The time elapsed 
between the start of treatnent and subsidence of symptoms appeared to be 
prolonged in patients with an infectious focus. A larger bacterial load in 
these infections could be an explanation, since the penetration of 
ceftazidime in the different tissues has been shown to reach adequate 
bactericidal levels (34,35). Treatment with a synergistic combination, 
including ceftazidime, may shorten the duration of illness and, 
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Table VII 
Ei'ipinc Therapy of Localised Infections in the Neutropenic Host 
Antibiotic(3) 
Aminoylyc. + pon. 
AmnoRlyc. + ceph. 
Double beca-lactan 
Honobactara + vaneo 
Penicillin + vaneo 
Ceftazidime alone 
Reference(s) 
4,6,10-12 
5,7,12 
3,6,9 
9 
8 
23-26 (this 
I 
study) 
N 
1137 
285 
788 
100 
193 
284 
Total 
61% 
6« 
597. 
682 
65Z 
81% 
FUO 
59% 
63Γ. 
632 
67% 
60% 
91% 
P-SEP 
73% 
74Z 
11% 
86% 
78% 
7AZ 
S-SEP 
39% 
-
uuz 
_ 
_ 
73% 
URTI 
86% 
_ 83% 
_ 
_ 94% 
LRTI 
45% 
57% 
36% 
42% 
37% 
84% 
SSTI 
77', 
62™ 
62% 
80% 
71% 
65% 
UTI 
92% 
100% 
88% 
100% 
100% 
88% 
FUO - Fever of Unknown Origin, P-SEP - Primary Septicemia, S-SEP - Secondary Septicemia, URTI - Upper 
Respiratory Tract Infection, LRTI - Louer Respiratory Tract Infection, SSTI - Skin and Soft Tissue 
Infection, UTI - Urinary Tract Infection, Aminoglyc • aminoglycoside, pen - penicillin, ceph β 
cephalosporin, vaneo - vancomycin. 
consequently, the length of treatnent required in patients with localized 
infections. This hypothesis however, needs corroboration in a prospective 
study and has to be weighed against the possibly higher toxicity of such a 
combination. 
Ten out of 12 (33%) URTI and 16 out of 29 (55%) LRTI which failed empirical 
ceftazidine monotherapy proved to be associated with a fungal infection. 
Йоге than half of the mycotic LRTI were fatal despite systemic antifungal 
therapy. Early diagnosis of mycotic infections in these patients is 
difficult. Neither serology, nor culturing proved to be reliable indicators 
of fungal invasion (36,37). Early empirical institution of systemic 
antifungal therapy may be beneficial especially in patients with URTI and 
LRTI not improving on initially instituted anti-bacterial therapy. 
It may be stated that empirically instituted ceftazidime monotherapy is a 
safe and well tolerated strategy in febrile neutropenic patients with a 
localized infection. Its efficacy is not hampered by localization of the 
infection and the results obtained compare favourably with established 
combinations especially in LRTI (Table VII). The addition of a specifically 
anti-staphylococcal compound in patients suspected of a catheter associated 
infection may be beneficial. Early systemic antifungal therapy should be 
considered in case empirical nonotherapy fails in LRTI or URTI. 
IH 
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CHAPTER 10 
SUMMARY SAMENVATTING 
TREATMENT OF BACTERIOLOGICAL INFECTIONS IN 
NEUTROPENIC PATIENTS WITH SPECIAL EMPHASIS 
ON CEFTAZIDIME MONOTHERAPY. 
Chapter 1 An introduction is given to infectious complications in the 
immunocompromised host. Retrospective analysis of all patients with acute 
leukemia admitted between 1972 and 1985 at the St. Radboud Hospital 
(Nijmegen) has shown an infection related mortality of 50%. Prevention, 
diagnosis and possible treatment Modalities have been discussed. The 
attention was focussed on empiric monotherapy with ceftazidime in febrile 
neutropenic patients. 
Chapter 2 An outline of the studies performed and their specific 
objectives are given. 
Chapter 3 In an earlier study ceftazidime monotherapy has proven to be 
significantly more effective for the treatment of febrile neutropenic 
patients than gentamicin plus cefotaxime. However, in case of infections 
caused by Gram-positive pathogens, ceftazidime is less effective than 
"earlier generations" of cephalosporins. The combination of ceftazidime 
plus cephalothin is compared with ceftazidime alone in a prospective 
randomized trial for empiric treatment of 102 febrile neutropenic patients. 
A cure of 72% has been achieved in both arms of the study. The combination 
proves to be slightly more effective, though not significant, in case of 
staphylococcal infections. When лесеззагііу, vancomycin has been added 
after 48 to 72 hrs. The ultimate outcome is not affected by this delay and 
does not warrant earlier empiric institution of a more broad spectrum and 
possibly more toxic combination. 
Chapter 4 In this chapter we compare the the efficacy and safety of a new 
formulation of ceftazidime (CAZ) "CAZ-arginine" (CAZ-ARG) with the marketed 
blend of CAZ sodium (CAZ-S). The latter is known for its practical 
drawback, on disolving it may generate папу small nop toxic bubbles in the 
infusion lines. CAZ-ARG lacks this disadvantage. The clinical cure rate for 
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100 febrile neutropenic patients treated in this prospective randomized 
trial is 91% (CAZ-S) and 83% (CAZ-ARG). Dacteriological clearance has been 
achieved in 37% for CAZ-S and G1% for CAZ-ARG respectively. The nurses in 
the ward préfères CAZ-ARG being easier to handle and less time consuming to 
prepare. [Jo difference in efficacy or safety of both formulations has been 
found. 
Chapter 5 Although ceftazidime monotherapy proves to be effective in the 
majority of febrile neutropenic patients, still a minority with infections 
due to Gram-positive microorganisms need modification. In this chapter we 
report the results of a pilot study about the efficacy and safety of 
teicoplanin, a new glycopeptide antibiotic related to vancomycin, as 
modification therapy in case of failure after initial empiric ceftazidime 
monotherapy. Teicoplanin is easy to apply (once daily push injection 
intravenously of 200 rag), and has been chosen for a possible lack of 
nephrotoxicity and ototoxicity. Twenty patients are included in this study. 
Clinical cure is achieved in 11 out of 16 assessable cases (69«), and 10 
out of 11 (91%) bacteriologically confirmed infections has been cured after 
addition of teicoplanin. No nephrotoxicity or ototoxicity is encountered, 
but 4 patients has shown a transient rise in liver transaminases. There is 
a large interindividual variation in serum levels attained and the mean 
through level remaines below the UIC 90 of staphylococci until day 7 of 
therapy. Provisional figures of an ongoing study with higher daily dosis of 
teicoplanin may suggest an increased chance on hepatotoxicity and 
ototoxicity. The question of a safe and reliable dosing schedule remains 
open, although the efficacy of teicoplanin in this small group neutropenic 
patients with infections due to Gram-positive pathogens has been shown. 
Chapter 6 Any empiric therapy in neutropenic patients must provide 
evidence of efficacy in Gram-riegative infections. The efficacy of 
ceftazidime monotherapy has been reviewed for Pseudomonas aeruginosa 
septicemia in neutropenic patients. Dacteriological clearance has been 
achieved in all by ceftazidime alone. Only 1 out of 29 patients died due to 
a cerebral hemhorhage on the 6th day of treatment. In localized infections 
subsidence of pyrexia and symptoms has taken longer than in patients with 
primary septicemia, although the eventual outcome has not been hampered in 
case secondary septicemia did occur. 
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Chapter 7 Patients undergoing allogeneic bone marrow transplantation are 
treated empirically with ceftazidine monotherapy in case fever occurs. No 
enhancement of the well known nephrotoxicity of cyclosporin-A is observed 
during therapy. The overall clinical cure rate of ceftazidime alone in 
these patients is 72:J, bacteriological clearance is achieved in бЗІО only, 
due to the higher incidence of resistant Gram-positive nicroorganisns in 
these patients. I'e conclude that ceftazidime monotherapy is a safe 
alternative for potentially nephrotoxic combination regimens in the empiric 
treatment of febrile neutropenic patients treated concomitantly with 
cyclosporin-Α, if one is prepared to niodify therapy in case a resistant 
Gram-positive organisms is encountered. 
Chapter G Drug related toxicodermia occurs frequently in patients with 
acute non lymphocytic leukemia. Drugs like allopurinol, co-trimoxazole, 
miconazole and ketoconazole are significantly more often associated with 
skinreactions during remission induction, than during maintenance therapy. 
Penicillin therapy is interrupted in 12% of these patients due to this 
complication. The overall incidence of skin reactions due to cephalosporins 
renaines low (3%, ρ 0.001) and only one patient has developed a rash 
related to ceftazidime. 
Chapter 9 Localized infections responds less favourably to therapy than 
infections without known focus. On thorough examination 44% of the febrile 
neutropenic patients shows a localization of the infection. The 
distribution of pathogens is not the sane for the different locations. 
Especially systemic fungal infections are mainly associated with infections 
of the tractus respiratorius. Gram-negative microorganisms are the major 
pathogen in urinary tract and lower tractus respiratorius infections, while 
Gram-positive pathogens are isolated more frequently in primary septicemia 
or skin and soft tissue infections. In the latter ceftazidime monotherapy 
does need modification significantly more often in order to cure the 
patient. Patients without focus responds faster with subsidence of symptoms 
and pyrexia than those with a proven focus of infection and needs less 
therapy to cure. Although the efficacy of ceftazidime to eradicate a 
pathogen is not hampered by tissue localization, synergistic combination 
therapy may be beneficial in case of a localized infection, but this 
hypothesis still needs confirmation. 
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Infection has been the major sole cause of mortality in patients with 
hematological diseases cor.iplicated by granulocytopenia during the past 
three decades. The incidence of infection related mortality is diminishing 
during the past 7 years in the St. Radboud hospital. Selective gut 
decontamination, early institution of therapy, experience developed during 
the past trials and last but not least the avai labi Ility of potent 
antibiotics like ceftazidime may all have influenced this outcome. 
Ceftazidine has proven to be a reliable and less toxic alternative for the 
conventional combination regimens as empiric therapy for febrile 
neutropenic patients. Infections due to Gram-positive pathogens occurs more 
often in patients with skin and soft tissue tissue infections, during 
septicemia or after bone marrow transplantation. Ceftazidime is less 
effective against these pathogens, though an extension of the therapy step 
by step has been shown a safe alternative for initial broadspectrum 
combination therapy and may reduce additional costs and complications. 
Ceftazidime is expensive. Out to compare the costs of combination therapy 
one must consider also the increase of associated workload, use of extra 
infusion sets. Monitoring of serum levels and possible side effects, or 
treatment in case coMplications do occur, besides the extra costs of the 
chosen antibiotics. 
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SAi'iE.IVATTIMG 
DE BEHANDELING VAN BACTERIELE INFECTIES BIJ NEUTHOPEilISCHE PATIENTEN 
ÜET SPECIAAL AANDACHT VOOR flONOTHERAPY I1IDDELS CEFTAZIDIIiE. 
Hoofdstuk 1 Een inleiding in de problematiek van infecties bij patiënten 
met granulocytopenie wordt gegeven. Uit retrospectief onderzoek blijkt dat 
50% van de patiënten net acute leukemie opgenomenin het St. Radboud 
ziekenhuis in de periode 1972-1985 is konen te overlijden ten gevolge van 
een infectie. Гюдеііjkheden ter preventie, opsporing en behandeling konen 
aan de orde. Hierbij uordt n.n. ingegaan op de vroegtijdige empirische 
behandeling van de granulocytopenische patient net koorts. Voor- en 
nadelen van de conventionele combinatie therapien worden besproken evenals 
de eerste resultaten van nonotherapy r.tet ceftazidime, een derde generatie 
Cephalosporine. 
Hoofdstuk 2 Hierin komen de verschillende vraagpunten aan de orde on de 
plaats van ceftazidime monotherapie bij een granulocytopenische patient met 
koorts nader te bepalen. 
hoofdstuk 3 Uit een eerder verricht onderzoek is gebleken, dat ceftazidime 
monotherapie significant effectiever is dan de combinatie van gentaraicine 
met cefotaxime bij de behandeling van de granulocytopenische patient met 
koorts. Echter bij infecties veroorzaakt door Gram-positieve 
microorganismen is ceftazidime minder werkzaam dan de eerdere generaties 
Cephalosporinen. Dit hoofdstuk handelt over onderzoek naar de effectiviteit 
van de combinatie ceftazidime en cephalothin in vergelijking met die van 
ceftazidime alleen. Volgens een prospectief gerandomizeerde wijze zijn 102 
patiënten met de combinatie of monotherapie behandeld. In beide armen van 
de studie is een genezing bereikt bij 72% van de behandelde patiënten. 
Alleen bij infecties veroorzaakt door staphylococcen lijkt de combinatie 
meer effectief zonder echter een statistische limiet van significantie te 
bereiken. Na 43 tot 72 uur is de behandeling met vancomycine uitgebreid 
voor die patiënten die onvoldoende reageerden op de empirisch ingestelde 
therapie. De uiteindelijke genezing is hierdoor niet beïnvloed. Uit de 
resultaten van dit onderzoek hebben wij geconcludeerd, dat toevoeging van 
cephalothin aan ceftazidime geen wezenlijke bijdrage vormt voor de 
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empirische therapie van de neutropenische patient net koorts en dat 
uitbreiding achteraf net een breedspectrun antie Gram-positief middel na 
falen van de initiële therapie de patient een mogelijk onnodige behandeling 
en eventuele bijwerkingen bespaart. 
Hoofdstuk 4 De handelsvorm van ceftazidime is gemengd net natrium 
bicarbonaat om de oplosbaarheid te verbeteren. Een praktisch nadeel hiervan 
is de vorning van kooldioxide bij het oplossen, met als gevolg een 
toegenone druk in de flacon en de vorming van vele, zij het onschadelijke, 
kleine belletjes in de toevoerleidingen van het infuus. In een gecombineerd 
onderzoek met de verpleegkundige staf zijn wij de effectiviteit en 
veiligheid van een andere vorm van ceftazidime, een arginine verbinding, 
.nagegaan. De effectiviteit bij 50 granulocytopenische patiënten met koorts 
blijkt vergelijkbaar te zijn met die van het natrium zout. Voor de 
verpleegkundigen echter blijkt ceftazidime arginine een duidelijk voordeel 
door de afwezigheid van gasvorming bij gereedmaken van het infuus en 
daardoor minder verlies van tijd en materiaal dan bij verwerking van het 
conventionele preparaat. 
Hoofdstuk 5 Ceftazidime alleen voldoet niet in een klein aantal patiënten 
met infecties tgv. Gram-positieve organismen. Teicoplanin, een antibioticum 
verwant aan vaneomycine, is op zijn waarde onderzocht als additionele 
behandeling bij falen van ceftazidime monotherapie. De mogelijk kleinere 
kans op nephro- en ototoxiciteit en eenvoud van toediening (lx daags 
intraveneuze injectie van 200 mg) hebben mede de keuze van dit niddel 
bepaald. Aan 20 granulocytopenische patiënten met persisterende koorts 
ondanks het gebruik van ceftazidime is teicoplanin aan de behandeling 
toegevoegd. Vier patiënten zijn afgevallen daar achteraf blijkt, dat hun 
koorts niet door een Gran-positief organisme is veroorzaakt. Elf (69«) van 
de overige 16 patiënten zijn genezen en 10 van de 11 geïsoleerde 
nicroorganismen zijn geëlimineerd. Gehoorsstoornissen of afwijkingen in de 
nierfunktie hebben zich niet voorgedaan. Wel is bij 4 patiënten een 
tijdeljke stoornis van de leverfunkties aangetoond. Ondanks de goede 
resultaten bij deze kleine groep patiënten bestaat twijfel over de juiste 
dosering van dit middel. De dalspiegels blijken laag. Gemiddeld is pas na 7 
dagen behandeling de UIC 90 voor Staphylococcus epiderniidis bereikt, 
hetgeen toch een van de meest frequent voorkomende, multiresistente. Gram-
positief organisme is in deze patiënten groep. De eerste resultaten van een 
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vervolg studie net hogere dosering laat echter mogelijk ook een toename van 
de bijwerkingen zien. Teicoplanin kan effectief zijn als additionele 
therapie bij neutropenische patiënten net koorts die niet verbeteren op 
ceftazidine alleen, echter de juiste dosering moet nog vastgesteld worden. 
hoofdstuk 6 Infecties net Gram-negatieve bacteriën blijken, indien niet 
snel en adequaat behandeld, in een a twee dagen fataal te zijn voor het 
merendeel van de granulocytopenische patiënten. ledere behandeling van een 
infectie in deze patiënten groep dient dan ook ten minste effectief te zijn 
tegen deze pathogenen. Het meest beruchte en moeilijkst te behandelen 
organisme is Pseudomonas aeruginosa. Analyse van alle granulocytopenische 
patiënten die een sepsis met Pseudomonas aeruginosa doorgemaakt hebben en 
in eerste instantie met ceftazidime alleen zijn behandeld, wordt in dit 
hoofdstuk besproken. Alle patiënten (29) zijn genezen,'op een na die na ó 
dagen behandeling is gestorven ten gevolge van een hersenbloeding. !Jel is 
gebleken, dat in patiënten iiiet een plaatselijke onsteking de koorts en 
klachten langer aanhouden en de behandeling ook langer doorgezet is noeten 
worden, dan in patiënten net sepsis zonder aanwijsbaar focus. 
Hoofdstuk 7 Bekend is het probleen van nierfunktie stoornissen ten gevolge 
van cyclosporine-Л, welke toegepast wordt bij allogene beenmerg 
transplantatie om afstoting te voorkomen. De conventionele combinaties van 
antimicrobiele middelen neigen tot versterking van de nephrotoxiciteit van 
dit middel. In dit hoofdstuk beschrijven wij het onderzoek naar het effect 
van ceftazidime op de nierfunktie tijdens cyclosporine gebruik. De 
nierfunktie blijkt hierdoor niet verder aangetast te worden. De 
effectiviteit van ceftazidime alleen in deze groep patiënten blijkt 72% te 
zijn. De genezing van bacteriologisch aangetoonde infecties is 63% bij een 
hoge incidentie van Gram-positieve niicroorganismen. Ceftazidime vormt een 
goed alternatief voor combinatie therapie na beenmerg transplantatie, ter 
voorkoming van nierfunktiestoornissen bij gelijktijdig gebruik van 
cyclosporine-A, indien men erop verdacht is de behandeling aan te passen 
zogauw zich een infectie met een resistent Gram-positief organisme 
voordoet. 
Hoofdstuk 3 De behandeling van patiënten met acute myeloide leukemie wordt 
gecompliceerd door een frequent voorkomen van door geneesmiddelen 
veroorzaakte huidreakties. Veel gebruikte middelen als allopurinol, co-
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trimoxazole, miconazole en ketoconazole zijn bij remissie inductie en na 
recidief significant vaker geassocieerd met huidreakties dan in perioden 
van remissie. Dij 12Γ; van deze patiënten moet de behandeling aangepast 
worden tgv. een huidreaktie door penicilline derivaten hetgeen significant 
vaker is dan na het gebruik van cephalosporines (3%, ρ 0.001). Slechts 
eenmaal heeft zich een huiduitslag tgv. ceftazidine voorgedaan. 
Hoofdstuk 9 Uit de literatuur blijkt dat infecties met een aantoonbaar 
focus minder goed reageren op behandeling dan infecties zonder duidelijke 
orgaan localisatie. Ter nadere evaluatie van de mogelijke rol van 
ceftazidime bij de behandeling van gelocaliseerde infecties zijn alle, tot 
1986 met ceftazidime nonotherapie behandelde patiënten, opnieuw 
geanalyseerd. Bij 44% van hen wordt een focus aangetoond. Schimels blijken 
vaker voor te komen bij infecties in de luchtwegen. Gran-negati eve 
pathoijenen worden vaker fjeisoleerd bij een infectie van de urinewegen of 
bronchopneunonie. Gram-positieve microorganismen blijken vaker 
verantwoordelijk voor een sepsis zonder focus en voor een weke delen 
infectie. Alleen in dit laatste geval is modificatie van ceftazidime 
monotherapie significant vaker noodzakelijk dan in de overige 
gelocaliseerde infecties. Tenslotte blijkt dat, indien zich een 
gelocaliseerde infectie voordoet, de koortsperiode en klachten langer 
aanhouden en behandeling langduriger voortgezet noet worden dan bij 
infecties zonder aanwijsbaar focus. Hogelijk zal combinatie therapie in 
deze gevallen zinvol kunnen zijn, het bewijs hiervoor is echter nog niet 
geleverd. 
Tot voor kort zijn infecties de belangrijkste doodsoorzaak geweest voor 
patiënten net een hematologische aandoening gecompliceerd door 
granulocytopenie al dan niet na chemotherapie. Er bestaan aanwijzingen dat 
de mortaliteit tgv infecties afneemt gedurende de laatste 7 jaar in deze 
kliniek. Factoren die hierop van invloed kunnen zijn geweest zijn de 
introduktie van selectieve damdecontaminatie, de vroegtijdige behandeling 
van de granulocytopenische patient net koorts, de ervaring die opgedaan is 
tijdens onderzoek en de introduktie van neer potente anti-microbiele 
middelen zoals ceftazidime. 
Uit de verschillende studies blijkt dat ceftazidime monotherapie 
niet onderdoet voor conventionele combinatie therapie, met als voornaamste 
voordeel een lage toxiciteit gepaard gaande aan eenvoud van toediening. 
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Patienten net koorts zonder aanwijsbaar focus, of net weke delen aandoening 
dan wel na beenmerg transplantatie lopen een verhoogd risiko op infecties 
door Gram-positieve microorganismen. Ceftazidime is minder werkzaam tegen 
deze organismen, echter een stapsgewijze uitbreiding van de behandeling 
lijkt een veilig alternatief voor een initiële breedspectrum combinatie 
therapie. Deze opstelling kan de patient mogelijke bijwerkingen besparen en 
beperkt de totale kosten van behandeling. De hoge kosten van ceftazidiine 
zelf vormen een nadeel. Echter, de extra kosten van conbinatie therapie in 
de vorm van een toename van: arbeid, infuussystemen, spiegel bepalingen, 
kans op toxiciteit en daardoor noodzakelijke monitoring van funkties en of 
beschermende maatregelen, dienen mede berekend te worden naast de koster 
van de middelen zelf in de uiteindelijke keuze van de behandelino. 
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Allen, die aan de totstandkoning van dit proefschrift hebben bijgedragen, 
wil ik danken. Allereerst de patiënten voor hun onmisbare medewerking aan 
het onderzoek. De verpleegkundigen van de afdeling A51 (bloedziekten St. 
riadboud ziekenhuis), т.п. Rose-lïarie Jansen (destijds waarnemend 
hoofdverpleegkundige), Tineke Tijsemus en Ui Ina Du Bois, voor hun niet 
aflatende zorg en interesse in de patient, de vele malen dat zij bloed en 
andere specimen afnanen ongeacht het uur van de dag of nacht en de zorg 
waardoor de verschillende protocollen gehandhaafd konden blijven. Ook ben 
ik dank verschuldigd aan het laboratorium bloedziekten en aan de afdeling 
iledische Microbiologie. Drs. L. Stalpers, Drs. E.' Ubachs en Drs. A Hoes zou 
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material and correction of the English text, even more so for his 
willingness to discuss these itens at odd hours in Hotels throughout 
Europe. Also I am obliged to Mr. P. Donnelly (Hammersmith Hospital, London, 
U.K.). Aan de stimulerende sfeer, medewerking en interesse van de stafleden 
van de afdeling Bloedziekten is mede te danken dat dit proefschrift 
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Hogere Buryer School ü behaalde. Aansluitend studeerde hij geneeskunde aan 
de Katholieke Universiteit van liijmegen. In 1974 trad hij in het huwelijk 
met Mieke Derks en samen verichtten zij gedurende een half jaar 
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(Koninklijk Instituut voor de Tropen; Hoofd ter velde: Drs. P. 
Verstraaten). Na het artsexanen in 197o bekuaande hij zich verder in de 
chirurgie, verloskunde en gynaecologie in het Koningin Juliana ziekenhuis 
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STELLINGEN 
1 Antibiotica vormen de belangrijkste anlipyretica voor neutropemsche patiënten. 
(Sickles et al • Arch. Intern Med. (1975) 135, 715-719. 
Klastersky : Rev. Infect Dis (19Θ3) 5, S21-S31) 
2. Ceftazidime monotherapie is even effectief als traditionele combinaties van antibiotica bij de 
behandeling van neutropemsche patiënten met koorts 
(Dit proefschnft) 
3. Ceftazidime monotherapie als empirische behandeling van de neutropemsche patient met koorts 
verdient de voorkeur bij gelijktijdig gebruik van potentieel nefro- of ototoxische middelen 
(Dit proefschrift) 
4. BIJ het bepalen van een behandelmgsstrategie van een neutropemsche patient met koorts dient 
rekening gehouden te worden met de eventuele localisatie van de infectie. 
(Dit proefschrift) 
5. De kans op door geneesmiddelen geïnduceerde huidreakties is verhoogd bij patiënten met een 
gecompromiteerde immuniteit. 
(Dit proefschrift) 
6. De handdruk van een arts bergt een groter risiko in zich op overdracht van pathogène micro-
orgamsmen dan gebruik van het toilet. 
(Semmelweis . Die Aetiologie, der Begriff und die Prophylaxis des Kindbettfiebers (1861). 
Just : Infections in the immunocompromised host. Symp (nov. 86) Nijmegen) 
7. De verschuiving van Gram-negatieve naar Gram-positieve verwekkers van infecties bij 
neutropemsche patiënten kan met toegeschreven worden aan de toepassing ' » " selectieve darm-
decontammatie alleen. 
(Guiot 4th. Int. Symp Inf. Immunocomp. Host, Ronneby (1986), Abstr. 92) 
θ Overleving vormt de belangrijkste parameter voor de effectiviteit van een antibioticum bij een 
neutropemsche patient met bewezen infectie. 
(Pizzo . N. Eng J. Med. (1986) 315; 552-558) 
9. Het voorschrijven van buscopan suppositona bij darmkrampen of kolieken is alleen al op grond 
van farmacologische gegevens irrationeel te noemen. 
(Martmdale, The Extra Pharmacopoeia, (1982) 28th Ed London) 
10 Hoewel de converting enzyme remmers vooral zijn ontworpen voor de behandeling van patiënten 
met renovasculaire hypertensie lijken ze juist bij deze patiënten in toenemende mate gecontram-
diceerd 
(Hoefnagels . Neth. J. Med (1984) 27, 269-274) 
11. De supenonteit van de nieuwe Polychemotherapie kuren zoals PROMACE-MOPP en M-BACOD 
bij maligne lymfomen over de meer traditionele combinaties zoals CHOP en MOPP is met bewezen. 
(Laurence . Ann. Intern Med (1982) 97, 190-195 
Fisher Ann. Intern. Med (1983) 98, 304-309 
Shipp Ann. Intern Med (1986) 104; 757-765) 
12. Interferon alpha heeft de voorkeur boven splenectomie bij de behandeling van Hairy cell leukemie 
(Porzsolt. Blut (1986) 52, 265-272) 
13. Toename van de effectiviteit van orale rehydratie vloeistof door ontwikkeling van meer verfijnde 
commerciële preparaten gaat ten koste van de bereikbaarheid. 
Thuis bereidde oplossingen op basis van zout met suiker of rijst verdienen dan ook de voorkeur. 
(Werner (1979). Where there is no doctor 
Molla The Lancet (1982) I; 1317-1319) 
14. Om medische redenen verdienen gebieden met een minder intense malana transmissie prioriteit 
te worden gegeven in de bestrijding van deze ziekte 
(WHO Expert Committee on Malana 18th report, Geneva 1986 
Phillips : Quaterly J. Med. (1986) 227, 305-328) 
15 Dat de subfaculteit der geneeskunde te Nijmegen "Hersenen en Gedrag" als zwaartepunt heeft 
gekozen, geeft te denken. 
16. BIJ ongebreideld bevolkingsonderzoek wordt voorkomen duurder dan genezen. 
Nijmegen, 22 januari 1987 Verhagen C A H.H V.M. 


ІФІФІ&ІЪТаІ&ЁІТ^аІФІаІаІ^аТаІ^шіШш^тті^Шітішш^ ш&Шішшшш^нШфШ 
»OOOOOOOOO« 
i'S'STS'STSTSTSTS^TSTí 
& 
•ооооооооооооооооооо» 
OOOOOOOÔÔÔOOOOOOOOOOOOOOOOOOOOOOOOOOOO· 
OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOQO« 
